Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals

Abstract

The present invention provides recombinant expression constructs comprising nucleic acid encoding mammalian melanocortin receptors, and mammalian cells into which said recombinant expression constructs have been introduced that express functional mammalian melanocortin receptors. The invention provides a panel of such transformed mammalian cells expressing melanocortin receptors for screening compounds for receptor agonist and antagonist activity. The invention also provides methods for using such panels of melanocortin receptor-expressing mammalian cells to specifically detect and identify agonists and antagonists for each melanocortin receptor, as well as patterns of agonist and antagonist activity of said compounds for the class of melanocortin receptors. Such screening methods provide a means for identifying compounds with patterns of melanocortin agonist and antagonist activity which are associated with the capacity to influence or modify metabolism and behavior, particularly feeding behavior.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to the cloning, expression and functional characterization of mammalian melanocortin receptor genes. The invention provides nucleic acid encoding mammalian melanocortin receptors, recombinant expression constructs comprising said nucleic acid, and mammalian cells into which said recombinant expression constructs have been introduced, and that express functional mammalian melanocortin receptors. The invention also provides a panel of such transformed mammalian cells expressing melanocortin receptors for screening compounds for receptor agonist and antagonist activity. The invention provides methods for using such panels of melanocortin receptor-expressing mammalian cells to specifically detect and identify agonists and antagonists for each melanocortin receptor, as well as patterns of agonist and antagonist activity of said compounds for the class of melanocortin receptors. Such screening methods provide a means for identifying compounds with patterns of melanocortin agonist and antagonist activity which are associated with the capacity to influence or modify physiological funtion and behavior, particularly metabolism and feeding behavior.

2. Background of the Invention

The proopiomelanocortin (POMC) gene product is processed to produce a large number of biologically active peptides. Two of these peptides, .alpha.-melanocyte stimulating hormone (.alpha.MSH), and adrenocorticotropic hormone (ACTH) have well understood roles in control of melanocyte and adrenocortical function, respectively. Both of these hormones are also found in a variety of forms with unknown functions, for example, .gamma.-melanocyte stimulating hormone (.gamma.MSH), which has little or no ability to stimulate pigmentation (Ling et al., 1979, Life Sci. 25: 1773-1780; Slominski et al., 1992, Life Sci. 50: 1103-1108). A melanocortin receptor gene specific for each of the .alpha.MSH, ACTH and .gamma.MSH hormones has been discovered by some of the present inventors (see U.S. Pat. Nos. 5,280,112, 5,532,347 and U.S. application Ser. No. 08/044,812, incorporated by reference herein). In addition, two other melanocortin receptor genes have been discovered by some of the present inventors (see Lu et al, 1994, Nature 371: 799-802; Mountjoy et al, 1994, Molec. Endocrinol. 8: 1298-1308) and others (see Gantz et al., 1993, J. Biol. Chem. 268: 15174-15179 and Labbe et al., 1994, Biochem. 33: 4543-4549).

Along with the well-recognized activities of .alpha.MSH in melanocytes and ACTH in adrenal and pituitary glands, the melanocortin peptides also have a diverse array of biological activities in other tissues, including the brain and immune system, and bind to specific receptors in these tissues with a distinct pharmacology (see, Hanneman et al., in Peptide Hormone as Prohormones, G. Martinez, ed. (Ellis Horwood Ltd.: Chichester, UK) pp. 53-82; DeWied & Jolles, 1982, Physiol. Rev. 62: 976-1059 for reviews). A complete understanding of these peptides and their diverse biological activities requires the isolation and characterization of their corresponding receptors. Some biochemical studies have been reported in the prior art.

Shimuze, 1985, Yale J. Biol. Med. 58: 561-570 discusses the physiology of melanocyte stimulating hormone.

Tatro & Reichlin, 1987, Endocrinology 121: 1900-1907 disclose that MSH receptors are widely distributed in rodent tissues.

Sola et al., 1989, J. Biol. Chem. 264: 14277-14280 disclose the molecular weight characterization of mouse and human MSH receptors linked to radioactively and photoaffinity labeled MSH analogues.

Siegrist et al., 1991, J. Receptor Res. 11: 323-331 disclose the quantification of receptors on mouse melanoma tissue by receptor autoradiography.

Cone & Mountjoy, U.S. patent application Ser. No. 07/866,979, filed Apr. 10, 1992, disclose the isolation of human and mouse .alpha.-MSH receptor genes and uses thereof (incorporated herein by reference).

Cone & Mountjoy, U.S. patent application Ser. No. 07/866,560, filed Apr. 10, 1992, disclose the isolation of human and bovine ACTH receptor genes and uses thereof (incorporated herein by reference).

Mountjoy et al., 1992, Science 257: 1248-1251 disclose the isolation of cDNAs encoding mammalian ACTH and MSH receptor proteins.

POMC neurons are present in only two regions of the brain, the arcuate nucleus of the hypothalamus, and the nucleus of the solitary tract of the brain stem. Neurons from both sites project to a number of hypothalamic nuclei known to be important in feeding behavior, including the paraventricular nucleus, lateral hypothalamic area, and ventromedial hypothalamic nucleus. While previous reports have claimed both stimulatory and inhibitory effects of .alpha.-MSH on feeding behavior (see Shimizu et al., 1989, Life Sci. 45: 543-552; Tsujii et al., 1989, Brian Res. Bull. 23: 165-169), knowledge of specific melanocortin receptors, their location within the central nervous system and the necessary pharmacological tools were not sufficiently developed at that time to allow the resolution of this issue. The present inventors have shown herein that a novel antagonist of the MC-3 and MC-4 melanocortin receptors can substantially increase food consumption in animals engaged in normal or fast-induced feeding behavior. This is consistent with expression of both MC-3 and MC-4 receptor mRNAs at these sites in in situ hybridization studies (Roselli-Rehfuss et al., 1993, Proc. Natl. Acad. Sci. USA 90: 8856-8860; Mountjoy et al., 1994, Molec. Endocrinol. 8: 1298-1308). Moreover, the regulation of arcuate nucleus POMC gene expression is consistent with an inhibitory role for POMC in feeding behavior. POMC mRNA levels are decreased following a fast (Bergendahl et al., 1992, Neuroendocrinol. 56: 913-920; Brady et al., 1990, Neuroendocrinol. 52: 441-447), and a significant diurnal variation in POMC mRNA levels in the arcuate nucleus is seen in rat, with the nadir occurring around the onset of nighttime feeding at 1800 hrs (Steiner et al., 1994, FASEB J. 8: 479-488).

Thus, the experimental evidence indicates that POMC neurons play an important role in tonic inhibition of feeding behavior, wherein obesity results from a chronic disruption of this inhibitory tone by antagonism of central melanocortin receptors in at least one animal model (agouti).

These results reveal for the first time a need in the art for a means for characterizing mammalian melanocortin receptor agonists and antagonists in vitro for the development of compounds that affect feeding behavior in animals.

SUMMARY OF THE INVENTION

The present invention provides a biological screening system for identifying and characterizing compounds that are agonists or antagonists of mammalian melanocortin receptors. The biological screening system of the invention comprises a panel of transformed mammalian cells comprising a recombinant expression construct encoding a mammalian melanocortin receptor, and expressing said receptor thereby. The invention provides such a panel of transformed mammalian cells wherein the panel comprises cells expressing each type of mammalian melanocortin receptor. Thus, the invention also provides nucleic acid encoding mammalian melanocortin receptors, recombinant expression constructs comprising said nucleic acid, and mammalian cells into which said recombinant expression constructs have been introduced, and that express functional mammalian melanocortin receptors. Methods for using such panels of melanocortin receptor-expressing mammalian cells to specifically detect and identify agonists and antagonists for each melanocortin receptor, as well as patterns of agonist and antagonist activity of said compounds for the class of melanocortin receptors, are also provided. Such screening methods provide a means for identifying compounds with patterns of melanocortin agonist and antagonist activity which are associated with the capacity to influence or modify metabolism and behavior in an animal, particularly feeding behavior.

Thus, the invention provides in a first aspect a biological screening panel for determining the melanocortin receptor agonist/antagonist profile of a test compound. The panel comprises a first mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the .alpha.-MSH (MC-1) receptor. The panel also comprises a second mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the ACTH (MC-2) receptor. The panel also comprises a third mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-3 receptor. The panel also comprises a fourth mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-4 receptor. The panel also comprises a fifth mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-5 receptor. As provided by the invention, each mammalian cell expresses the melanocortin receptor encoded by the recombinant expression construct comprised by said cell.

In preferred embodiments, the melanocortin receptors encoded by the recombinant expression constructs comprising the transformed mammalian cells comprising the panel are mouse MC-1 receptor (SEQ ID Nos.: 3 and 4); human MC-1 receptor (SEQ ID Nos.: 5 and 6), human MC-2 (ACTH) receptor (SEQ ID Nos.: 7 and 8), bovine MC-2 receptor (SEQ ID Nos.: 9 and 10), rat MC-3 receptor (SEQ ID Nos.: 11 and 12), human MC-4 receptor (SEQ ID Nos.: 15 and 16) and human MC-5 receptor (SEQ ID Nos.: 17 and 18).

In a second aspect, the invention provides a method for using the melanocortin receptor panel to identify and characterize test compounds as melanocortin receptor agonists and/or antagonists. In this embodiment, the method provided by the invention identifies a melanocortin receptor agonist, and comprises the steps of contacting each of the cells of the panel with a test compound to be characterized as an agonist of a mammalian melanocortin receptor and detecting binding of the test compound to each of the mammalian melanocortin receptors by assaying for a metabolite produced in the cells that bind the compound. In a preferred embodiment, the detected metabolite is cAMP.

In a preferred embodiment of this method, each of the cells of the panel of mammalian cells expressing mammalian melanocortin receptors further comprises a recombinant expression construct encoding a cyclic AMP responsive element (CRE) transcription factor binding site that is operatively linked to a nucleic acid sequence encoding a protein capable of producing a detectable metabolite. In preferred embodiments, said protein is .beta.-galactosidase, most preferably encoded by a nucleic acid comprising the recombinant expression construct identified as pCRE/.beta.-galactosidase (as disclosed in Chen et al., 1994, Analyt. Biochem. 226: 349-354). As provided by the invention, expression of the protein that produces the detectable metabolite is dependent on binding of the test compound to the melanocortin receptor expressed by each cell in the panel and the intracellular production of cAMP as a result. In this embodiment, cAMP production results in expression of a protein capable of producing a detectable metabolite, the protein most preferably being .beta.-galactosidase. In preferred embodiments, the detectable metabolite absorbs light to produce a colored product. Thus, this embodiment of the invention provides a panel of melanocortin receptor-expressing cells whereby melanocortin hormone binding results in the production of a colored product in proportion to the extent of cAMP production in the cell as a result of hormone receptor binding.

In another embodiment of this aspect of the invention is provided a method for characterizing a compound as an antagonist of a mammalian melanocortin receptor. In this embodiment, the method comprises the steps of contacting each of the cells of the panel with an agonist of the mammalian melanocortin receptor in an amount sufficient to produce a detectable amount of a metabolite produced in the cells that bind the agonist, in the presence or absence of a test compound to be characterized as an antagonist of a mammalian melanocortin receptor, and detecting the amount of the metabolite produced in each cell in the panel in the presence of the test compound with the amount of the metabolite produced in each cell in the panel in the absence of the test compound. As provided by the assay, inhibition of the production of the detectable metabolite is used as an indication that the tested compound is a melanocortin receptor antagonist, which is further characterized quantitatively by the extent of said inhibition.

In a preferred embodiment of this method, each of the cells of the panel of mammalian cells expressing mammalian melanocortin receptors further comprises a recombinant expression construct encoding a cyclic AMP responsive element (CRE) transcription factor binding site that is operatively linked to a nucleic acid sequence encoding a protein capable of producing a detectable metabolite. In preferred embodiments, said protein is .beta.-galactosidase, most preferably encoded by a nucleic acid comprising the recombinant expression construct identified as pCRE/.beta.-galactosidase. As provided by the invention, expression of the protein that produces the detectable metabolite is dependent on binding of the test compound to the melanocortin receptor expressed by each cell in the panel. In preferred embodiments, the detectable metabolite absorbs light to produce a colored product. Thus, this embodiment of the invention provides a panel of melanocortin receptor-expressing cells whereby melanocortin hormone binding results in the production of a colored product in proportion to the extent of cAMP production in the cell as a result of hormone receptor binding.

The invention also provides melanocortin receptor agonists identified by the methods and using the screening panel of the invention. In preferred embodiments, the agonist is an agonist of the MC-3 mammalian melanocortin receptor. In preferred embodiments, the agonist is an agonist of the MC-4 mammalian melanocortin receptor.

The invention provides melanocortin receptor antagonists identified by the methods and using the screening panel of the invention. In preferred embodiments, the antagonist is an antagonist of the MC-3 mammalian melanocortin receptor. In preferred embodiments, the antagonist is an antagonist of the MC-4 mammalian melanocortin receptor.

The invention also provides methods for characterizing mammalian melanocortin receptor agonists for the capacity to modify or influence metabolism and feeding behavior in an animal. In a first aspect, the invention provides a method for characterizing melanocortin receptor MC-3 or MC-4 agonists as inhibitors of feeding behavior in an animal, the method comprising the steps of providing food to an animal that has been deprived of food for at least 12 hours, with or without administering to the animal an MC-3 or MC-4 receptor agonist of the invention, and comparing the amount of food eaten by the animal after administration of the MC-3 or MC-4 receptor agonist with the amount of food eaten by the animal without administration of the MC-3 or MC-4 receptor agonist.

In another aspect, the invention provides a method for characterizing a melanocortin MC-3 or MC-4 receptor antagonist as a stimulator of feeding behavior in an animal. In this embodiment, the method comprises the steps of providing food to an animal not deprived of food for at least 12 hours, with or without administering to the animal an MC-3 or MC-4 receptor antagonist, immediately prior to the onset of darkness or nighttime, and comparing the amount of food eaten by the animal after administration of the MC-3 or MC-4 receptor antagonist with the amount of food eaten by the animal without administration of the MC-3 or MC-4 receptor antagonist.

Thus, the invention also provides methods for using certain of the melanocortin receptor agonists and antagonists for modifying feeding behavior in an animal. In a first aspect, the invention provides a method for stimulating feeding in an animal, the method comprising administering to the animal an MC-3 or MC-4 receptor antagonist. In a preferred embodiment, the antagonists are administered systemically. In additional embodiments, the antagonists are administered intracerebroventricularly.

In another aspect, the invention provides a method for inhibiting feeding in an animal, the method comprising administering to the animal an MC-3 or MC-4 receptor agonist. In a preferred embodiment, the agonists are administered systemically. In additional embodiments, the agonists are administered intracerebroventricularly.

In yet another aspect, the invention provides mammalian melanocortin receptor agonists having the general formula:

A-B-C-D-E-F-G-amide wherein A is an aliphatic amino acid residue, including for example Leu, Ile, Nle and Met, as well as analogues and substituted derivatives thereof; B is an acidic amino acid residue, including for example Asp and Glu; C is a basic amino acid residue, such as His; D is an aromatic amino acid residue having a D- conformation, including D-Phe, D-Tyr and substituted derivatives thereof; E is a basic amino acid residue, for example Arg, Lys, homoArg, homoLys, and analogues or substituted derivatives thereof; F is Trp or substituted derivatives thereof; and G is Lys, homoLys or a substituted derivative thereof. In the peptide embodiments of the melanocortin receptor agonists of the invention, the peptide is cyclized by the formation of an amide bond between the side chain carboxyl group of the Asp or Glu residue at position B in the peptide, and the side chain amino group of the Lys or homoLys residue at position G. In preferred embodiments, the melanocortin receptor agonists of the invention are agonists of the MC-3 or MC-4 receptor.

The invention also provides mammalian melanocortin receptor antagonists having the general formula:

A-B-C-D-E-F-G-amide wherein A is an aliphatic amino acid residue, including for example Leu, Ile, Nle and Met, as well as analogues and substituted derivatives thereof; B is an acidic amino acid residue, including for example Asp and Glu; C is a basic amino acid residue, such as His; D is an aromatic amino acid residue having a D- conformation, including D-Nal and substituted derivatives thereof; E is a basic amino acid residue, for example Arg, Lys, homoArg, homoLys, and analogues or substituted derivatives thereof; F is Trp or substituted derivatives thereof; and G is Lys, homoLys or a substituted derivative thereof. In the peptide embodiments of the melanocortin receptor antagonists of the invention, the peptide is cyclized by the formation of an amide bond between the side chain carboxyl group of the Asp or Glu residue at position B in the peptide, and the side chain amino group of the Lys or homoLys residue at position G. In preferred embodiments, the melanocortin receptor antagonists of the invention are agonists of the MC-3 or MC-4 receptor.

It is an advantage of the present invention that it provides an in vitro screening method for characterizing compounds having melanocortin receptor binding activities that relate to feeding behavior in animals. Specifically, the invention advantageously provides means and methods for identifying compounds having melanocortin receptor agonist and/or antagonist activity that have been associated with either stimulating or inhibiting feeding behavior when administered to an animal. The invention thus provides an economical first step in screening compounds for the capacity to affect feeding behavior, including synthetic, peptidomimetic or organomimetic derivatives of melanocortin receptor agonists or antagonists as disclosed herein or elsewhere.

Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.

DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B illustrate the nucleotide (SEQ ID No.: 3) and amino acid (SEQ ID No.: 4) sequence of the mouse melanocyte stimulating hormone receptor gene.

FIGS. 2A and 2B illustrate the nucleotide (SEQ ID No.: 5) and amino acid (SEQ ID No.: 6) sequence of the human melanocyte stimulating hormone receptor gene.

FIGS. 3A and 3B illustrate the nucleotide (SEQ ID No.: 7) and amino acid (SEQ ID No.: 8) sequence of the human adrenocorticotropic hormone receptor gene.

FIGS. 4A and 4B illustrate the nucleotide (SEQ ID No.: 9) and amino acid (SEQ ID No.: 10) sequence of the bovine adrenocorticotropic hormone receptor gene.

FIGS. 5A and 5B illustrate the nucleotide (SEQ ID No:11) and amino acid (SEQ ID No.:12) sequences of the rat melanocortin-3 receptor.

FIGS. 6A and 6B illustrate the nucleotide (SEQ ID No.: 15) and amino acid (SEQ ID No.: 16) sequence of the human melanocortin 4 receptor gene.

FIGS. 7A and 7B illustrate the nucleotide (SEQ ID No: 17) and amino acid (SEQ ID No.: 18) sequences of the rat melanocortin-5 receptor gene.

FIG. 8 shows a graph of intracellular cAMP accumulation resulting from melanocyte stimulating hormone receptor agonist binding in human 293 cells transfected with a MSH receptor-encoding recombinant expression construct.

FIG. 9 illustrates the cAMP response of mouse Y1 cells to binding of melanocortin peptides to human melanocortin-2 (ACTH) receptor, as measured using the .beta.-galactosidase assay described in Example 4.

FIG. 10 illustrates the results of competition binding experiments of melanocortin peptides to cells expressing a recombinant expression construct encoding the rat melanocortin-3 receptor.

FIGS. 11A through 11C illustrate the results of experiments showing intracellular cAMP accumulation caused by receptor-ligand binding in human 293 cells expressing the MC-3 receptor.

FIG. 12 shows a graph of intracellular cAMP accumulation resulting from peptides to human melanocortin-4 receptor agonist binding in human 293 cells transfected with a MC-4 receptor-encoding recombinant expression construct.

FIG. 13 illustrates the results of cAMP accumulation (AC) and cAMP-dependent .beta.-galactosidase (.beta.-gal) assays of melanocortin peptide binding to a rat melanocortin-5 receptor.

FIG. 14 illustrates the structure of the pCRE/.beta.-gal plasmid.

FIGS. 15A through 15D illustrates the results of the .beta.-galactosidase-coupled, colorimetric melanocortin receptor binding assay using cells expressing each of the MC-1, MC-3, MC-4 or MC-5 receptors and contacted with .alpha.MSH or a variety of .alpha.MSH analogues.

FIGS. 16A through 16D shows the results of the .beta.-galactosidase-coupled, colorimetric melanocortin receptor binding assay to determine antagonist activity of melanocortin analogues SHU9119 and SHU8914 in cells expressing each of the melanocortin receptors MC-1, MC-3, MC-4 and MC-5.

FIGS. 17A and 17B shows the results of classic competition binding assays using the melanocortin analogues SHU9119 and SHU8914 at the MC3R and MC-4 R receptors.

FIGS. 18A and 18B shows the results of cAMP accumulation experiments (performed using the .beta.-galactosidase assay of Example 4) for mouse MC-4 receptor (FIG. 18A) and rat MC-5 receptor (FIG. 18B).

FIGS. 19A through 19C show the effect on food intake of intracerebroventricular administration of melanocortin analogue SHU9119 in mice.

FIGS. 20A through 20C show the effect on food intake of intracerebroventricular administration of melanocortin analogue MTII in mice.

FIG. 20D shows the effect on locomotor activity of intracerebroventricular administration of melanocortin analogue MTII in mice.

FIGS. 21A through 21D show the effect on food intake of intracerebroventricular administration of melanocortin analogue MTII in mice.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The term "melanocortin receptor" as used herein refers to proteins having the biological activity of any of the disclosed melanocortin receptors, including the MC-1 (SEQ ID Nos.: 3, 4, 5 and 6), MC-2 (ACTH; SEQ ID Nos.: 7, 8, 9 and 10), MC-3 (SEQ ID Nos.: 11 and 12), MC-4 (SEQ ID Nos.: 15 and 16) or MC-5 (SEQ ID Nos.: 17 and 18) receptors, as well as naturally-occurring and genetically-engineered allelic variations in these sequences.

Cloned nucleic acid provided by the present invention may encode MC receptor protein of any species of origin, including, for example, mouse, rat, rabbit, cat, and human, but preferably the nucleic acid provided by the invention encodes MC receptors of mammalian, most preferably rodent and human, origin.

The production of proteins such as the MC receptors from cloned genes by genetic engineering means is well known in this art. The discussion which follows is accordingly intended as an overview of this field, and is not intended to reflect the full state of the art.

DNA which encodes MC receptors may be obtained, in view of the instant disclosure, by chemical synthesis, by screening reverse transcripts of mRNA from appropriate cells or cell line cultures, by screening genomic libraries from appropriate cells, or by combinations of these procedures, as illustrated below. Screening of mRNA or genomic DNA may be carried out with oligonucleotide probes generated from the MC receptor gene sequence information provided herein. Probes may be labeled with a detectable group such as a fluorescent group, a radioactive atom or a chemiluminescent group in accordance with know procedures and used in conventional hybridization assays, as described in greater detail in the Examples below. In the alternative, MC receptor gene sequences may be obtained by use of the polymerase chain reaction (PCR) procedure, with the PCR oligonucleotide primers being produced from the MC receptor gene sequences provided herein. See U.S. Pat. Nos. 4,683,195 to Mullis et al. and 4,683,202 to Mullis.

MC receptor proteins may be synthesized in host cells transformed with a recombinant expression construct comprising a nucleic acid encoding each of the receptors disclosed herein. Such a recombinant expression construct can also be comprised of a vector that is a replicable DNA construct. Vectors are used herein either to amplify DNA encoding an MC receptor and/or to express DNA which encodes an MC receptor. For the purposes of this invention, a recombinant expression construct is a replicable DNA construct in which a DNA sequence encoding an MC receptor is operably linked to suitable control sequences capable of effecting the expression of the receptor in a suitable host cell. The need for such control sequences will vary depending upon the host selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and translation. Amplification vectors do not require expression control domains. All that is needed is the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants. See, Sambrook et al., 1990, Molecular Cloning: A Laboratorv Manual (Cold Spring Harbor Press: New York).

Also specifically provided by the invention are reporter expression constructs comprising a nucleic acid encoding a protein capable of expressing a detectable phenotype, such as the production of a detectable reporter molecule, in a cell expressing the construct. Such constructs can be used for producing recombinant mammalian cell lines in which the reporter construct is stably expressed. Most preferably, however, the reporter construct is provided and used to induce transient expression over an experimental period of from about 18 to 96 hrs in which detection of the reporter protein-produced detectable metabolite comprises an assay. Such reporter expression constructs are also provided wherein induction of expression of the reporter construct is controlled by a responsive element operatively linked to the coding sequence of the reporter protein, so that expression is induced only upon proper stimulation of the responsive element. Exemplary of such a responsive element is a cAMP responsive element (CRE), which induces expression of the reporter protein as a result of an increase in intracellular cAMP concentration. In the context of the present invention, such a stimulus is associated with melanocortin receptor binding, so that a reporter construct comprising one or more CREs is induced to express the reporter protein upon binding of a receptor agonist to a MC receptor in a recombinantly transformed mammalian cell. Production and use of such a reporter construct is illustrated below in Example 5.

Vectors useful for practicing the present invention include plasmids, viruses (including phage), retroviruses, and integratable DNA fragments (i.e., fragments integratable into the host genome by homologous recombination). The vector replicates and functions independently of the host genome, or may, in some instances, integrate into the genome itself. Suitable vectors will contain replicon and control sequences which are derived from species compatible with the intended expression host. A preferred vector is the plasmid pcDNA/neo I. Transformed host cells are cells which have been transformed or transfected with recombinant expression constructs made using recombinant DNA techniques and comprising mammalian MC receptor-encoding sequences. Preferred host cells are human 293 cells. Preferred host cells for the MC-2 (ACTH) receptor are Y1 cells (subclone OS3 or Y6). Transformed host cells are chosen that ordinarily express functional MC receptor protein introduced using the recombinant expression construct. When expressed, the mammalian MC receptor protein will typically be located in the host cell membrane. See, Sambrook et al., ibid.

Cultures of cells derived from multicellular organisms are a desirable host for recombinant MC receptor protein synthesis. In principal, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. However, mammalian cells are preferred, as illustrated in the Examples. Propagation of such cells in cell culture has become a routine procedure. See Tissue Culture, Academic Press, Kruse & Patterson, editors (1973). Examples of useful host cell lines are human 293 cells, VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, mouse Y1 (subclone OS3), and WI138, BHK, COS-7, CV, and MDCK cell lines. Human 293 cells are preferred.

Cells expressing mammalian MC receptor proteins made from cloned genes in accordance with the present invention may be used for screening agonist and antagonist compounds for MC receptor activity. Competitive binding assays are well known in the art and are described in the Examples below. Such assays are useful for drug screening of MC receptor agonist and antagonist compounds, as detected in receptor binding assays as described below.

One particular use of such screening assays is for developing drugs and other compounds useful in modifying or changing feeding behavior in mammals. The invention provides an assay system, comprising a panel of recombinant mammalian cells, heterologously expressing each of the MC receptors disclosed herein, wherein the panel is constructed of at least one cell line expressing an MC receptor. The invention provides such panels also comprising a detection means for detecting receptor agonist or antagonist binding, such as the reporter expression constructs described herein, using direct binding and competition binding assays as described in the Examples below. In the use of this panel, each MC receptor is assayed for agonist or antagonist patterns of binding a test compound, and a characteristic pattern of binding for all MC receptors is thereby determined for each test compound. This pattern is then compared with known MC receptor agonists and antagonists to identify new compounds having a pattern of receptor binding activity associated with a particular behavioral or physiological effect.

For example, provided herein is experimental evidence that MC-3 or MC-4 receptor antagonists are capable of stimulating feeding in sated animals, and that MC-3 or MC-4 agonists are capable of inhibiting feeding in animals otherwise stimulated to eat. The invention provides an in vitro assay to characterize MC-3 and MC-4 agonists/antagonists as a preliminary and economical step towards developing feeding behavior-modulating drugs for use in vivo.

These results on feeding behavior in vivo have been obtained with certain MC receptor binding analogues, SHU9119 and MTII. These compounds have the following chemical structure: ##STR1## (An additional analogue, SHU8914, has been tested in in vitro receptor binding assays; this compound is identical in structure to SHU9119, except that the amino acid analogue at position 7 is para-iodo-D-phenylalanine.)

Generally, those skilled in the art will recognize that peptides as described herein may be modified by a variety of chemical techniques to produce compounds having essentially the same activity as the unmodified peptide, and optionally having other desirable properties. For example, carboxylic acid groups of the peptide, whether carboxyl-terminal or sidechain, may be provided in the form of a salt of a pharmaceutically-acceptable cation or esterified to form a C.sub.1 -C.sub.16 ester, or converted to an amide of formula NR.sub.1 R.sub.2 wherein R.sub.1 and R.sub.2 are each independently H or C.sub.1 -C.sub.16 alkyl, or combined to form a heterocyclic ring, such as 5- or 6-membered. Amino groups of the peptide, whether amino-terminal or sidechain, may be in the form of a pharmaceutically-acceptable acid addition salt, such as the HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric and other organic salts, or may be modified to C.sub.1 -C.sub.16 alkyl or dialkyl amino or further converted to an amide. Hydroxyl groups of the peptide sidechain may be converted to C.sub.1 -C.sub.16 alkoxy or to a C.sub.1 -C.sub.16 ester using well-recognized techniques. Phenyl and phenolic rings of the peptide sidechain may be substituted with one or more halogen atoms, such as fluorine, chlorine, bromine or iodine, or with C.sub.1 -C.sub.16 alkyl, C.sub.1 -C.sub.16 alkoxy, carboxylic acids and esters thereof, or amides of such carboxylic acids. Methylene groups of the peptide sidechains can be extended to homologous C.sub.2 -C.sub.4 alkylenes. Thiols can be protected with any one of a number of well-recognized protecting groups, such as acetamide groups. Those skilled in the art will also recognize methods for introducing cyclic structures into the peptides of this invention to select and provide conformational constraints to the structure that result in enhanced binding and/or stability. For example, a carboxyl-terminal or amino-terminal cysteine residue can be added to the peptide, so that when oxidized the peptide will contain a disulfide bond, thereby generating a cyclic peptide. Other peptide cyclizing methods include the formation of thioethers and carboxyl- and amino-terminal amides and esters.

Peptidomimetic and organomimetic embodiments are also hereby explicitly declared to be within the scope of the present invention, whereby the three-dimensional arrangement of the chemical constituents of such peptido- and organomimetics mimic the three-dimensional arrangement of the peptide backbone and component amino acid sidechains in the peptide, resulting in such peptido- and organomimetics of the peptides of this invention having substantial biological activity. It is implied that a pharmacophore exists for the receptor agonist and antagonist properties of these and related MC receptor binding analogues. A pharmacophore is an idealized, three-dimensional definition of the structural requirements for biological activity. Peptido- and organomimetics can be designed to fit each pharmacophore with current computer modeling software (computer aided drug design). MC receptor binding analogues derived using such software and comprising peptido- and organomimetics of SHU9119 and MTII and related analogues are within the scope of the claimed invention.

The MC receptor binding analogues, in particular those analogues that are MC-3 or MC-4 receptor agonists or antagonists are provided to be used in methods of influencing, modifying or changing feeding behavior in mammals in vivo. Specific examples of uses for the MC receptor binding analogues of the invention include but are not limited to treatment of eating disorders such as anorexia and obesity, and other pathological weight and eating-related disorders. Other examples are failure to thrive disorders and disease-related cachexia, such as occurs in cancer patients. Also within the scope of the analogues of the invention is use for enhancing appearance, athletic ability, or adjuvant to other therapies to treat disorders such as high blood pressure, high serum cholesterol, vascular and heart disease, stroke, kidney disease, diabetes and other metabolic disorders.

The Examples which follow are illustrative of specific embodiments of the invention, and various uses thereof. They set forth for explanatory purposes only, and are not to be taken as limiting the invention.

EXAMPLE 1

Isolation of an .alpha.MSH Receptor Probe by Random PCR Amplification of Human Melanoma cDNA Using Degenerate Oligonucleotide Primers

In order to clone novel G-protein coupled receptors, cDNA prepared from RNA from human melanoma cells was used as template for a polymerase chain reaction (PCR)-based random cloning experiment. PCR was performed using a pair of degenerate oligonucleotide primers corresponding to the putative third and sixth transmembrane regions of G-protein coupled receptors (Libert et al., 1989, Science 244: 569-72; Zhou et al., 1990, Nature 347: 76-80). The PCR products obtained in this experiment were characterized by nucleotide sequencing. Two novel sequences representing novel G-protein-coupled receptors were identified.

PCR amplification was performed as follows. Total RNA was isolated from a human melanoma tumor sample by the guanidinium thiocyanate method (Chirgwin et al., 1979, Biochemistry 18: 5294-5299). Double-stranded cDNA was synthesized from total RNA with murine reverse transcriptase (BRL, Gaithersburg, Md.) by oligo-dT priming (Sambrook et al., ibid.). The melanoma cDNA mixture was then subjected to 45 cycles of PCR amplification using 500 picomoles of degenerate oligonucleotide primers having the following sequence:

Primer III (sense):GAGTCGACCTGTG(C/T)G(C/T)(C/G)AT(C/T)(A/G)CIIT(G/T)GAC(C/A)G(C/G)TAC (SEQ ID NO:1)andPrimer VI (antisense):CAGAATTCAG(T/A)AGGGCAICCAGCAGAI(G/C)(G/A)(T/C)GAA (SEQ ID NO:2) in 100 .mu.l of a solution containing 50 mM Tris-HCl (pH 8.3), 2.5 mM MgCl.sub.2, 0.01% gelatin, 200 .mu.M each dNTP, and 2.5 units of Taq polymerase (Saiki et al., 1988, Science 239: 487-491). These primers were commercially synthesized by Research Genetics Inc. (Huntsville, Ala.). Each PCR amplification cycle consisted of incubations at 94.degree. C. for 1 min (denaturation), 45.degree. C. for 2 min (annealing), and 72.degree. C. for 2 min (extension).

Amplified products of the PCR reaction were extracted with phenol/chloroform and precipitated with ethanol. After digestion with EcoRl and SalI, the PCR products were separated on a 1.2% agarose gel. A slice of this gel, corresponding to PCR products of 300 basepairs (bp) in size, was cut out and purified using glass beads and sodium iodide, and the insert was then cloned into a pBKS cloning vector (Stratagene, LaJolla, Calif.).

A total of 172 of such pBKS clones containing inserts were sequenced using Sequenase (U.S. Biochemical Corp., Cleveland, Ohio) by the dideoxynucleotide chain termination method (Sanger et al., 1977, Proc. Natl. Acad. Sci. USA 74: 5463-5467). Two types of sequences homologous to other G-protein coupled receptors were identified.

EXAMPLE 2A

Isolation of a Mouse .alpha.MSH (MC-1) Receptor cDNA

Probes isolated in Example 1 were used to screen a Cloudman melanoma cDNA library in order to isolate a full-length cDNA corresponding to the cloned probe. One clone was isolated from a library of 5.times.10.sup.6 clones screened as described in co-owned U.S. Pat. No. 5,532,347, incorporated by reference. This clone contained an insert of 2.6 kilobases (kb). The nucleotide sequence of the complete coding region was determined (see co-owned U.S. Pat. No. 5,532,347, incorporated by reference); a portion of this cDNA comprising the coding region was sequenced and is shown in FIGS. 1A and 1B (SEQ ID Nos: 3 & 4).

EXAMPLE 2B

Isolation of a Human .alpha.MSH (MC-1) Receptor cDNA

In order to isolate a human counterpart of the murine melanocyte .alpha.MSH receptor gene disclosed in Example 2A and co-owned U.S. Pat. No. 5,532,347, a human genomic library was screened at high stringency (50% formamide, 42.degree. C.) using the human PCR fragments isolated as described in Example 1. A genomic clone was determined to encode an human MSH receptor (SEQ ID NO:5.; FIGS. 2A and 2B). The human MSH receptor has a predicted amino acid sequence (SEQ ID NO:6) that is 75% identical and colinear with the mouse .alpha.MSH receptor cDNA sequence. The predicted molecular weight of the human MSH receptor is 34.7 kD.

EXAMPLE 2C

Isolation of a Human ACTH (MC-2) Receptor cDNA

For cloning the ACTH receptor (MC-2), a human genomic library was screened at high stringency (50% formamide, 1M NaCl, 50 nM Tris-HCl, pH 7.5, 0.1% sodium pyrophosphate, 0.2% sodium dodecyl sulfate, 100 .mu.g/ml salmon sperm DNA, 10 .times.Denhardt's solution, 42.degree. C.), using the human PCR fragments isolated as described in Example 1 herein and U.S. Pat. No. 5,280,112, incorporated by reference. A genomic clone was isolated that encodes a highly related G-coupled receptor protein (SEQ ID No:7 and FIGS. 3A and 3B). The predicted amino acid sequence (SEQ ID NO:8) of this clone is 39% identical and also colinear, excluding the third intracellular loop and carboxy-terminal tail, with the human MSH receptor gene product. The predicted molecular weight of this putative ACTH receptor is 33.9 kilodaltons (kD). This clone was identified as encoding an MC-2 receptor based on its high degree of homology to the murine and human MSH receptors, and the pattern of expression in different tissue types, as described in Example 3 in U.S. Pat. No. 5,280,112, incorporated by reference herein.

EXAMPLE 2D

Isolation of a Bovine ACTH (MC-2) Receptor cDNA

A bovine genomic DNA clone encoding the bovine counterpart of the MC-2 (ACTH) receptor was isolated from a bovine genomic library, essentially as described in Example 2C above, and its nucleotide sequence determined (as shown in FIGS. 4A and 4B; SEQ ID Nos:9 & 10).

EXAMPLE 2E

Isolation of a Rat .gamma.-MSH (MC-3) Receptor cDNA

The mouse .alpha.MSH receptor cDNA isolated as described in Example 2A and co-owned U.S. Pat. No. 5,532,347 was used to screen a rat hypothalamus cDNA library at low stringency (30% formamide, 5.times.SSC, 0.1% sodium pyrophosphate, 0.2% sodium dodecyl sulfate, 100 .mu.g/ml salmon sperm DNA, and 10% Denhardt's solution) at 42.degree. C. for 18 h. A 1 kb cDNA clone was isolated and sequenced as described in co-owned U.S. Pat. No. 5,532,347, and this clone used to re-screen the rat hypothalamus cDNA library at high stringency (same conditions as above except that formamide was present at 45%). A cDNA clone approximately 2.0 kb in length was isolated and analyzed as described in co-pending U.S. application Ser. No. 08/044,812, incorporated by reference; a portion of this cDNA comprising the coding region was sequenced and is shown in FIGS. 5A and 5B (SEQ ID Nos:11 & 12).

EXAMPLE 2F

Isolation of a Human MC-4 Receptor DNA

For cloning the MC-4 receptor, a human genomic library was screened at moderate stringency (40% formamide, 1M NaCl, 50 mM Tris-HCl, pH 7.5, 0.1% sodium pyrophosphate, 0.2% sodium dodecyl sulfate, 100 .mu.g/ml salmon sperm DNA, 10 .times.Denhardt's solution, 42.degree. C.), using rat PCR fragments isolated as described in Example 1 herein, with the exception that the following primers were used for PCR:

Primer II (sense):GAGTCGACC(A/G)CCCATGTA(C/T)T(AGT)(C/T)TTCATCTG (SEQ ID NO:13)andPrimer VII (antisense):CAGAATTCGGAA(A/G)GC(A/G)TA(G/T)ATGA(A/G)GGGGTC (SEQ ID NO:14)

A genomic clone was isolated that encodes a highly related G-coupled receptor protein (SEQ ID NO:15 and FIGS. 6A and 6B) on a 1.9 kb HindIII fragment. The predicted amino acid sequence (SEQ ID NO:16) of this clone shares 55-61% sequence identity with human MC-3 and MC-5 receptors, and 46-47% sequence identity with the human MC-1 and MC-2 (ACTH) receptor.

EXAMPLE 2G

Isolation of a Mouse MC-5 Receptor DNA

One million clones from a mouse 129SVJ genomic library comprising 5,000,000 clones in the .lambda.FixII vector (Stratagene) were screened at low stringency (hybridization in 40% formamide at 42.degree. C., washing performed in 0.5.times.SSC at 60.degree. C., as described above in Example 2E) using radiolabeled probes from the rat MC-3 and MC-4 receptors, as described in Examples 2E and 2F. Positively-hybridizing clones were isolated and sequenced, and the sequences obtained were compared to previously-isolated melanocortin receptor clones. One clone, comprising a previously-unknown sequence, was determined to encode the MC-5 melanocortin receptor. The nucleotide and amino acid sequences of this receptor are shown in FIGS. 7A and 7B (SEQ ID No.: 17 & 18).

EXAMPLE 3

Construction of a Recombinant Expression Construct, DNA Transfection and Functional Expression of the MCR Gene Products

In order to produce recombinant mammalian cells expressing each of the melanocortin receptors of Example 2, cDNA or the coding exons from genomic DNA from each receptor was cloned into a mammalian expression construct, the resulting recombinant expression construct transfected into human 293 cells, and cell lines generated that expressed the melanocortin receptor proteins in cellular membranes at the cell surface.

The mouse .alpha.MSH receptor was cloned by excising the entire coding region of the .alpha.MSH.sup.R (MC-1) cDNA insert comprising a 2.1 kb fragment and subcloning this fragment into the BamHI/XhoI sites of pcDNAI/neo expression vector (Invitrogen, San Diego, Calif.). The resulting plasmid was prepared in large-scale through one cycle of CsCl gradient ultracentrifugation, and 20 .mu.g of the plasmid transfected into each 100 mm dish of 293 cells using the calcium phosphate method (see Chen & Okayama, 1987, Mol. Cell. Biol. 7: 2745-2752). After transfection, cells were cultured in DMEM media supplemented with 10% calf serum in a 3% CO.sub.2 atmosphere at 37.degree. C. Selection was performed with neomycin (G418; GIBCO) at a concentration of 1000 .mu.g/mL; selection was started 72 hr after transfection and continued for 3 weeks.

The .alpha.MSH receptor is known to couple to G-proteins and thereby activate adenyl cyclase, increasing intracellular levels of cAMP (see Buckley & Ramachandran, 1981, Proc. Natl. Acad. Sci. USA 78: 7431-7435; Grahame-Smith et al., 1967, J. Biol. Chem 242: 5535-5541; Mertz & Catt, 1991, Proc. Natl. Acad. Sci. USA 88: 8525-8529; Pawalek et al., 1976, Invest. Dermatol. 66: 200-209). This property of cells expressing the .alpha.MSH receptor was used analyze expression of the .alpha.MSH receptor in cell colonies transfected with the expression vectors described herein as follows. Cells (.about.1.times.10.sup.6) were plated in 6-well dishes, washed once with DMEM containing 1% bovine serum albumin (BSA) and 0.5 mM IBMX (a phosphodiesterase inhibitor), then incubated for 45 minutes at 37.degree. C. with varying concentrations of the melanotropic peptides .alpha.MSH, .beta.MSH, .gamma.MSH, the MSH peptide analogues Nle.sup.4, D-Phe.sup.7 -.alpha.MSH (NDP-MSH), and ACTH. Following hormone treatment, the cells were washed twice with phosphate buffered saline and intracellular cAMP extracted by lysing the cells with 1 mL of 60% ethanol. Intracellular cAMP concentrations were determined using an assay (Amersham) which measures the ability of cAMP to displace (8-.sup.3 H) cAMP from a high affinity cAMP binding protein (see Gilman, 1970, Proc. Natl. Acad. Sci. USA 67: 305-312).

The results of these experiments are shown in FIG. 8. The abscissa indicates the concentration of each hormone and the ordinate indicates the percentage of basal intracellular cAMP concentration achieved by each treatment. Points indicate the mean of duplicate incubations; the standard error did not exceed 15% for any data point. None of the peptides tested induced any change in intracellular cAMP in cells containing the vector alone. Cells expressing the murine .alpha.MSH receptor responded to melanotropic peptides with a 2-3 fold elevation of intracellular cAMP, similar to levels of cAMP induced by these peptides in the Cloudman cell line (see Pawalek, 1985, Yale J. Biol. Med. 58: 571-578). The EC.sub.50 values determined for .alpha.MSH (2.0.times.10.sup.-9 M), ACTH (8.0.times.10.sup.-9 M) and the superpotent MSH analogue NDP-MSH (2.8.times.10.sup.-11 M) correspond closely to reported values (see Tatro et al., 1990, Cancer Res. 50: 1237-1242). As expected, the .beta.MSH peptide had an EC.sub.50 value comparable to .alpha.MSH, while .gamma.MSH had little or no activity (see Slominski et al., 1992, Life Sci. 50: 1103-1108), confirming the identity of this receptor as a melanocyte .alpha.MSH receptor.

A similar series of experiments were performed using mouse Y1 cells (subclone OS3; Schimmer et al., 1995, J. Cell. Physiol. 163: 164-171) expressing the human and bovine MC-2 (ACTH) receptor clones of Examples 2C and 2D. These results are shown in FIG. 9, where the extent of cAMP responsive element-linked .beta.-galactosidase activity (see Example 4, below) is shown with increasing concentrations of ACTH.

The entire coding region of the MC-3 receptor cDNA insert, obtained as described above in the copending U.S. Ser. No. 08/044,812, was contained in a 2.0 kb restriction enzyme digestion fragment and was cloned into the BamHI/XhoI sites of pcDNA/neo I expression vector (Invitrogen, San Diego, Calif.). The resulting plasmid was prepared in large-scale through one cycle of CsCl gradient ultracentrifugation and 20 .mu.g pcDNA/MC-3 receptor DNA were transfected into each 100 mm dish of 293 cells using the calcium phosphate method (see Chen & Okayama, 1987, Mol. Cell. Biol. 7: 2745-2752). After transfection, cells were cultured in DMEM media supplemented with 10% calf serum in a 3% CO.sub.2 atmosphere at 37.degree. C. Selection was performed with neomycin (G418; GIBCO) at a concentration of 1000 .mu.g/mL; selection was started 72 h after transfection and continued for 3 weeks.

Specific binding of melanocortin peptides to cells expressing the MC-3 receptor was demonstrated by competition experiments using .sup.125 I-labeled Nle.sup.4 -D-Phe.sup.7 -.alpha.-MSH (NDP-MSH, as described in Tatro et al., 1990, Cancer Res. 50: 1237-1242). Suspended cells (2.times.10.sup.5) were incubated at 37.degree. C. with 500,000 cpm of labeled peptide for 10 min in binding buffer (Ham's F10 media plus 10 mM HEPES, pH 7.2, 0.25% bovine serum albumin, 500K IU/mL aprotinin, 100 .mu.g/mL bacitracin and 1 mM 1,10-phenanthroline) in the presence or absence of the indicated concentrations of peptides. Maximum labeling was achieved within 10 min.

The results of these experiments are shown in FIG. 10. Labeled NDP-MSH binding to cells expressing the MC-3 receptor, produced as described above, is inhibited by competition with unlabeled peptides known to be melanocortin receptor agonists, having a relative order of potency as follows:

NDP-MSH>.gamma.-MSH>.alpha.-MSH>ACTH.sub.4-10 >>>ORG2766. Approximate K.sub.i values derived from this experiment are as shown in Table I: TABLE I______________________________________Agonist K.sub.i (approx)______________________________________NDP-MSH 2 .times. 10.sup.-8.gamma.-MSH 5 .times. 10.sup.-8.alpha.-MSH 1 .times. 10.sup.-7ACTH.sub.4-10 8 .times. 10.sup.-5______________________________________

cAMP production assays as described above were also used to analyze expression of MC-3R in cells transfected with the expression vectors described herein as follows. Cells (.about.5.times.10.sup.6) were plated in 6-well dishes, washed once with DMEM containing 1% bovine serum albumin (BSA) and 0.5 mM IBMX (a phosphodiesterase inhibitor), then incubated for 1 h at 37.degree. C. with varying concentrations of the melanotropic peptides .alpha.MSH, .gamma..sub.3 MSH, .gamma.MSH, the MSH peptide analogues Nle.sup.4 -D-Phe.sup.7 -.alpha.MSH (NDP-MSH), ACTH.sub.4-10 and ACTH.sub.1-39. Following hormone treatment, the cells were washed twice with phosphate buffered saline and intracellular cAMP extracted by lysing the cells with 1 mL of 60% ethanol. Intracellular cAMP concentrations were determined using an assay which measures the ability of cAMP to displace (8-.sup.3 H) cAMP from a high affinity cAMP binding protein (see Gilman, 1979, Proc. Natl. Acad. Sci. USA 67: 305-312).

The results of these experiments are shown in FIGS. 11A through 11C. The abscissa indicates the concentration of each hormone and the ordinate indicates the percentage of basal intracellular cAMP concentration achieved by each treatment. Points indicate the mean of duplicate incubations; the standard error did not exceed 15% for any data point. FIG. 11A depicts the results of experiments using peptides found in vivo; FIG. 11B depicts results found with .gamma.-MSH variants; and FIG. 11C shows results of synthetic melanocortin analogues. None of the peptides tested induced any change in intracellular cAMP in cells containing the vector alone. Cells expressing rat MC-3R responded strongly to every melanotropic peptide containing the MSH code sequence His-Phe-Arg-Trp, with up to a 60-fold elevation of intracellular cAMP levels. EC.sub.50 values ranged from 1-50 nM. The most potent ligand and the one having the lowest EC.sub.50 was found to be .gamma.MSH. The order of potency for the naturally occurring melanocortins was found to be:

.gamma..sub.2 -MSH=.gamma.MSH>.alpha.MSH=ACTH.sub.1-39 >.gamma..sub.3 -MSH>des-acetyl-.alpha.MSH>ACTH.sub.4-10. EC.sub.50 values for these compounds are shown in Table II: TABLE II______________________________________Agonist EC.sub.50______________________________________NDP-MSH 1 .times. 10.sup.-9.gamma..sub.1 -MSH 3 .times. 10.sup.-9.gamma..sub.2 -MSH 3 .times. 10.sup.-9.alpha.-MSH 4 .times. 10.sup.-9ACTH.sub.1-39 4 .times. 10.sup.-9.gamma..sub.3 -MSH 6 .times. 10.sup.-9desacetyl-.alpha.MSH 8 .times. 10.sup.-9ACTH.sub.4-10 1 .times. 10.sup.-7______________________________________

Additionally, a synthetic melanocortin peptide (ORG2766), known to have the greatest activity in vivo in stimulation of retention of learned behavior and in stimulation of neural regeneration, was unable to stimulate MC-3R-mediated cAMP production, and was also inactive as an antagonist. The results strongly indicate that this peptide does not bind to MC-3R protein.

The MC-4 receptor was cloned in a 1.9 kb HindIII genomic DNA fragment after PCR amplification of a lambda phage clone into pcDNAI/Neo (Invitrogen). This plasmid was stably introduced into human 293 cells by calcium phosphate co-precipitation using standard techniques, and plasmid-containing cells selected in G418-containing media. Specificity of receptor-hormone binding was assayed using adenylate cylcase activity as described above. The MC-4 receptor was found to couple to adenylate cyclase activity having the following pattern of agonist affinity:

NDP-MSH>des-acetyl-.alpha.-MSH>/=ACTH.sub.1-39 >/=.alpha.-MSH>>.gamma..sub.2 -MSH=ACTH.sub.4-10 whereas the synthetic ACTH.sub.4-9 analogue ORG2766 showed no detectable binding to the MC-4 receptor. The results of adenylate cyclase activity assays are shown in FIG. 12. EC.sub.50 values for each of the tested MC-4 receptor agonists are as shown in Table III: TABLE III______________________________________Agonist EC.sub.50______________________________________NDP-MSH 1.1 .times. 10.sup.-11 Mdesacetyl-.alpha.MSH 4.9 .times. 10.sup.-10 MACTH.sub.1-39 6.8 .times. 10.sup.-10 M.alpha.-MSH 1.5 .times. 10.sup.-9 M.sup..gamma..sub.2 -MSH >10.sup.-7 MACTH.sub.4-10 >10.sup.-7 M______________________________________

A 1.6 kb ApaI-HindIII fragment comprising the entire coding sequence of the mouse MC-5 melanocortin receptor disclosed in Example 2G above was cloned into the pcDNA/neo expression vector (Invitrogen) after PCR amplification of the lambda phage clone. This plasmid was stably introduced into human 293 cells by calcium phosphate co-precipitation using standard techniques, and plasmid-containing cells selected in G418 containing media. Specificity of receptor-hormone binding was assayed using adenylate cylcase activity as described above. The MC-5 receptor was found to couple to adenylate cyclase activity having the following pattern of agonist affinity:

.alpha.-MSH>.beta.MSH>>.gamma.-MSH The results of adenylate cyclase activity assays (AC) and cAMP-dependent .beta.-galactosidase (.beta.-gal) assay are shown in FIG. 13. EC.sub.50 values for each of the tested MC-5 receptor agonists are: .alpha.-MSH=1.7.times.10.sup.-9 M; and .beta.MSH=5.times.10.sup.-9 M.

EXAMPLE 4

Melanocortin Analogue Binding to Mammalian Melanocortin Receptors

Recombinant cells prepared as described above in Example 3 were used to characterize receptor binding of two melanocortin analogues comprising cyclic lactam heptapeptides.

The melanocortin receptor analogue SHU9119 has the following chemical structure: ##STR2##

The melanocortin receptor analogue MTII has the following chemical structure: ##STR3##

These analogues were prepared as described in Hruby et al. (1995, J. Med. Chem. 38: 3454-3461).

These analogues were tested for melanocortin receptor binding using a calorimetric assay system developed by some of the instant inventors (Chen et al., 1995, Analyt. Biochem. 226: 349-354) as follows. A series of concatamers of the synthetic oligonucleotide:

5'-GAATTCGACGTCACAGTATGACGGCCATGG-3' (SEQ ID No:19) was produced by self-annealing and ligation and a tandem tetramer obtained. This fragment was cloned upstream of a fragment of the human vasoactive intestinal peptide (-93-+152; SEQ ID No.: 13; see Fink et al., 1988, Proc. Natl. Acad. Sci. USA 85: 6662-6666). This promoter was then cloned upstream of the .beta.-galactosidase gene from E. coli. The resulting plasmid construct is shown in FIG. 14.

Transient transfection of the pCRE/.beta.-gal plasmid described above was performed as follows. Cells at between 40-60% confluency (corresponding to about 1.5 million cells/6 cm tissue culture plate) were incubated with Opti-MEM (Gibco BRL, Long Island, N.Y.) and then contacted with a pCRE/.beta.-gal-lipofectin complex which was prepared as follows. 3 .mu.g plasmid DNA and 20 .mu.L lipofectin reagent (Gibco) were each diluted into 0.5 mL Opti-MEM media and then mixed together. This mixture was incubated at room temperature for 15-20 min., and then the mixture (1 mL) added to each 6 cm plate. Transfected plates were incubated at 37.degree. C. for 5-24 h, after which the plates were washed and incubated with DMEM media (Gibco) and the cells split equally into a 96-well culture plate.

To assay melanocortin receptor analogue binding, human 293 cells expressing each of the melanocortin receptors MC-1, MC-3, MC-4 and MC-5, and mouse Y1 cells expressing the MC-2 receptor, were transiently transfected with pCRE/.beta.-gal as described above and assayed as follows. Two days after transfection, cells were stimulated with hormones specific for each receptor or hormone analogue by incubation for 6 h at 37.degree. C. with a mixture comprising 10.sup.-12 -10.sup.-6 M hormone or analogue, 0.1 mg/mL bovine serum albumin and 0.1 mM isobutylmethylxanthine in DMEM. The effect of hormone or analogue binding was determined by .beta.-galactosidase assay according to the method of Felgner et al. (1994, J. Biol. Chem. 269: 2550-2561). Briefly, media was aspirated from culture wells and 50 .mu.L lysis buffer (0.25M Tris-HCl, pH 8/0.1% Triton-X100) added to each well. Cell lysis was enhanced by one round of freezing and thawing the cell/lysis buffer mixture. 10 .mu.L aliquots were sampled from each well for protein determination using a commercially-available assay (BioRad, Hercules, Calif.). The remaining 40 .mu.L from each well was diluted with 40 .mu.L phosphate buffered saline/0.5% BSA and 150 .mu.L substrate buffer (60 mM sodium phosphate/1 mM MgCl.sub.2 /10 mM KCl/5 mM .beta.-mercaptoethanol/200 .mu.g/mL o-nitrophenyl-.beta.-D-galactopyranoside) added. Plates were incubated at 37.degree. C. for 1 h and then absorbance at 405 nm determined using a 96-well plate reader (Molecular Devices, Sunnyvale, Calif.). A series of two-fold dilutions from 20 ng of purified .beta.-galactosidase protein (Sigma Chemical Co, St. Louis, Mo.) were assayed in parallel in each experiment to enable conversion of OD.sub.405 to known quantity of .beta.-galactosidase protein.

The results of these experiments are shown in FIGS. 15A through 15D. This Figure shows the results of the .beta.-galactosidase assay described above using cells expressing each of the MC-1, MC-3, MC-4 or MC-5 receptors and contacted with .alpha.MSH or a variety of .alpha.MSH analogues, including SHIU9119. These results showed that SHU9119 had relatively weak agonist activity for both the human MC-3 and MC-4 receptors.

These results demonstrated the development of a colorimetric assay for cAMP accumulation as the result of melanocortin receptor binding to agonists and antagonists.

The action of MTII, SHU9119, and the endogenous mouse agouti peptide as agonists or antagonists of rodent MC receptors was determined by examining their ability to elevate intracellular cAMP in 293 cell lines expressing the rat MC3-R or mouse MC4-R (expressed as IC.sub.50 values representing ligand concentrations required for half-maximal inhibition of binding of .sup.125 I-(Nle.sup.4,D-Phe.sup.7) .alpha.-MSH tracer). Agonist/antagonist activity was also shown by demonstrating inhibition of cAMP elevation by the potent .alpha.-MSH analogue (Nle.sup.4, D-Phe.sup.7).alpha.-MSH, using either a cAMP-responsive .beta.-galactosidase reporter construct as described above, or by direct adenyl cyclase assay as described in Example 3 (wherein EC.sub.50 values represent ligand concentration required for half-maximal activation of a cAMP-responsive .beta.-galactosidase reporter). Competition binding experiments were determined as the amount of radioactivity bound in the presence of 5.times.10.sup.-6 M cold (Nle.sup.4, D-Phe.sup.7).alpha.-MSH, and was typically 3-5% of total counts bound.

In these experiments, murine agouti peptide was produced using a baculovirus system as described by Lu et al., (1994, Nature 371: 799-802), with the modification that the agouti peptide was purified from baculovirus supernatants by 0.6M NaCl step clution from an EconoS cation exchange column (BioRad). Agouti peptide used in these assays was approximately 60% pure.

Competition binding assays were performed to determine whether SHU9119 had antagonist activity towards .alpha.MSH binding to either the MC-3 or MC-4 receptors. These assays were performed as follows. Human 293 cells (100,000 cells/well in 24-well plates) expressing either the MC-3 or MC-4 receptors prepared as described above were incubated with a solution of 1 mg/mL BSA in PBS containing 100,000 cpm (3.1.times.10.sup.-10 M (.sup.125 I)(Nle.sup.4, D-Phe.sup.7).alpha.MSH and varying concentrations of .alpha.MSH, (Nle.sup.4, D-Phe.sup.7).alpha.MSH or SHU9119. Cells were incubated for 30 min at 37.degree. C., washed twice with PBS-BSA, lysed with 0.5 mL 0.5N NaOH, and counted using a .gamma.-counter to quantitate the amount of bound (.sup.125 I)(Nle.sup.4, D-Phe.sup.7).alpha.MSH. Control experiments showed non-specific binding to occur at about 3-5% levels, and this was taken into account when analyzing the experimental results.

The SHU9119 analogue was found to be a potent antagonist of both the human MC-3 and MC-4 receptors, as shown in FIGS. 16A through 16D. These assays showed pA.sub.2 values of 8.3 and 9.3 for the human MC-3 and MC-4 receptors, respectively, as determined using the method of Schild (1947, Brit. J. Pharmacol. 2: 189-206). In contrast, no significant alteration in IC.sub.50 values was detected in binding experiments using this analogue with either the MC-3 or MC-4 receptors (FIGS. 17A and 17B).

The activity of the MTII analogue was also assayed for melanocortin receptor agonist activity. These results are shown in FIGS. 18A and 18B, and confirmed that the MTII analogue is a specific agonist of the MC-3 and MC-4 receptors.

Specific competition of (Nle.sup.4, D-Phe.sup.7).alpha.-MSH binding to the rat MC-3 receptor by agouti peptide was observed, although accurate IC.sub.50 values could not be determined because the peptide preparation was not homogeneous (results not shown). Specific competition of .alpha.MSH activation of human MC-4R by agouti was previously disclosed (Lu et al., 1994, Nature 371: 799-802).

EXAMPLE 5

Feeding Behavior Effect of Melanocortin Analogue Binding in Brain

The results shown in Example 4 above suggested a role in the regulation of feeding behavior in mammalian brain for MC receptor agonists and antagonists, in view of the antagonist properties of the agouti peptide at the MC-3 and MC-4 receptors. The agouti peptide was known to cause obesity when expressed ectopically in the mouse, and has been found to be a high affinity antagonist of the melanocyte stimulating hormone receptor (MC-1R) and of the hypothalamic MC-4 receptor (see Lu et al., ibid.). The former activity explained the inhibitory effect of the agouti peptide on eumelanin pigment synthesis. Similarly, it was hypothesized by the inventors that agouti causes obesity in mice by antagonizing hypothalamic MC-4 receptors. The cyclic melanocortin analogue, SHU9119, having been shown herein and elsewhere (Hruby et al., ibid.) to be a specific, high affinity antagonist of the MC-3 and MC-4 receptors, was tested for the effect of direct administration to mouse brain on feeding behavior in the animals. Intracerebroventricular (ICV) administration of SHU9119 was performed to avoid any complications caused by inhibition of peptide traverse of the blood-brain barrier.

Briefly, male C57B1/6J mice (18-29 g) were maintained on a normal 12 hr/12 hr light dark cycle with food (Purina mouse chow) and water ad libitum. Animals were housed individually for 24 hrs, distributed into experimental and control groups, avoiding any bias as a function of prior weight, then injected with vehicle or vehicle plus drug just prior to the onset of a 12 hr light or dark cycle. Fasted animals were deprived of food from 18:00 to 10:30 hrs to stimulate feeding during the daytime experimental period. Animals were lightly anesthetized with halothane, and administered into one lateral ventricle 2 .mu.L of a solution of artificial cerebrospinal fluid alone (acsf, comprising 130 mM NaCl, 27mM NaHCO.sub.3, 1.2 mM Na.sub.2 HPO.sub.4, 0.3 mM NaH.sub.2 PO.sub.4, 0.5 mM Na.sub.2 SO.sub.4, 1.0 mM CaCl.sub.2, 1.0 mM MgCl.sub.2, and 2.5 mM KCl), or 6 nmol SHU9119 in acsf. Freehand injections were performed as described by Laursen and Belknap (1986, J. Pharmacol. Methods 16: 355-357) with some modifications. A 10 .mu.l luertip syringe (Hamilton 701 LT) was fitted with a 0.5 inch 27 gauge needle. Stiff Tygon tubing was slipped over the needle to expose 3 mM of the needle tip. The syringe was held at a 45.degree. angle from the front of the skull with the bevel facing up. The coronal suture was found by lightly rubbing the needle over the skull. Maintaining the 45.degree. angle, the needle was then inserted 1-2 mm lateral to the midline, using only mild pressure to insert and remove the needle. The compounds indicated in a 2 .mu.l volume of acsf were administered slowly over approximately 15 seconds, and the needle removed after 35 seconds. Animals were allowed to recover from anesthesia and placed into a cage containing a premeasured quantity of food pellets in a spill-free cup. Moribund animals were not included in the study.

Stimulation of feeding by intracerebroventricular administration of the melanocortin antagonist SHU9119 is shown in FIGS. 19A through 19C. Curves show cumulative food intake as a function of time following administration of the substances shown. FIG. 19A shows stimulation of feeding by administration of SHU9119 just prior to lights off (19:00 hrs) to C57B 1/6J mice fed ad libidum. FIG. 19B, in contrast, shows no effect of morning (10:00 hrs) SHU9119 administration in C57B1/6J mice fed ad libidum. FIG. 19C illustrates stimulation of daytime feeding by SHU9119 administration in fasted C57B1/6J mice. In deriving the data points comprising these Figures, food remaining was briefly removed and weighted indica time intervals indicated. Data points indicate the mean and bars indicate standard error. Significance of the effect over time was determined by ANOVA with repeated measures. Significance of drug effects at individual time points was determined by two-way ANOVA, and is indicated in each Figure (***=P<0.001, **=P<0.01, *=P<0.05).

These results demonstrated that ICV administration of SHU9119 into one lateral ventricle of the C57B 1/6J mouse just prior to lights out led to a mean 60% increase in food intake over 12 hrs (FIG. 19A; P<0.005). In contrast, daytime food intake in animals fed ad libidum was not stimulated by administration of SHU9119 (FIG. 19B). SHU9119-treatment did, however, significantly stimulate daytime food intake in animals fasted for 16 hrs prior to the experiment (FIG. 19C; P<0.001). Stimulation of feeding was evident at approximately two hrs post-treatment, and continued for 12 hrs, to produce a mean 34% in food intake relative to vehicle-injected controls.

These results supported the hypothesis that agouti or SHU9119 stimulate feeding by antagonizing MC receptors in the central nervous system. To further test this hypothesis, a series of experiments were performed wherein MC receptor agonists were administered to animals primed by fasting to eat, to determine whether feeding in such animals could be inhibited by the MC receptor agonists. Animals were induced to feed by food deprivation for 16 h prior to ICV administration of the non-specific melanocortin agonist MTII. In these experiments, ICV injections in male C57B1/6J mice (20-30 g) and the measurement of food intake were as described above.

Results of these experiments are shown in FIGS. 20A through 20C. In comparison to vehicle-injected animals, MTII was found to produce a potent inhibition of feeding within one hour after administration (FIG. 20A) in a dose-responsive manner. Food intake was significantly inhibited for up to four hours following administration (P<0.001) at the highest dose administered (3 nmol), and decreased food intake continued for the next four hours with normal rates of food intake resuming at about 8 hours after treatment. This dose-responsive inhibition of feeding had an IC.sub.50 at the two hour time point of approximately 0.5 nmol (FIG. 20C). However, inhibition of feeding with 3 nmol MTII was completely blocked by co-administration of 6 nmol SHU9119 (FIG. 20B; P<0.001), demonstrating that the effect results specifically from agonist binding to the MC-4 and/or MC-3 receptor.

Locomotor assays were performed to determine whether the effects on feeding behavior observed in these mice were secondary to generalized behavioral effects caused by administration of these melanocortin analogues. The effects of MTII on locomotor activity were tested by placing vehicle or MTII-treated mice in sound and light-proof cages containing multiple light beam detectors. These assays were performed by first injecting 3 nmol MTII or acsf as described above. At three hours (2:45-3:25) post-injection, 12 mice were placed into 12 separate boxes containing multiple infrared light sources and photodetectors. The boxes were contained within separate ventilated light and sound attenuating chambers (Coulboum model E10-20). Disruption of the infrared beams, with a 10 msec. resolution, was tallied independently for each one minute time period in each cage. The results of these assays are shown in FIG. 20D. Data points indicate the mean total activity (# of light breaks) for 6 animals in each experimental group. Four way ANOVA statistical analysis was used to analyze the data, and indicated an absence of a significant difference among the two groups.

Inhibition of feeding by MTII could not be explained by any apparent behavioral abnormalities, or any effect on arousal or locomotor activity. MTII-treated animals appeared alert and exhibited no unusual behavior relative to controls. At approximately three hours after ICV administration, MTII-treated animals exhibited locomotor activity that was indistinguishable from vehicle-treated animals (FIG. 20D). The higher initial activity, indicative of exploratory behavior, and continued locomotion over a 15 min period was indistinguishable between the two groups, indicating that the inhibition of feeding was not due to decreased locomotion or decreased arousal.

The administration of MTII also inhibited food intake in three other models of hyperphagia: the C57B1/6J-Lep.sup.ob mouse, C57B1/6J-A.sup.Y mouse, and NPY-injected C57B/1/6J mouse. FIG. 21A shows inhibition of feeding by intracerebroventricular administration of MTII in A.sup.Y mice (females, 19-28 gms). FIG. 21B shows inhibition of feeding by intracerebroventricular administration of MTII in C57B1/6J mice (females, 21-25 gm) stimulated to feed by co-administration of neuropeptide Y. FIG. 21C shows inhibition of feeding by intracerebroventricular administration of the MTII in ob/ob mice (females, 48-69 gms). FIG. 21D shows inhibition of feeding in ob/ob mice intraperitoneal administration of MTII (females, 40-45 gms). ICV injections and measurement of food intake was performed as described above, with the exception of NPY treated animals, which were not fasted prior to experimentation. Animals treated intraperitoneally received 100 .mu.l of a 1 mM solution of MTII in saline, and vehicle injections consisted of the same value of saline alone. Significance indicated for individual time points, determined as described above, was for 3 nmol MTII vs. acsf (FIG. 21A), 1.18 nmol NPY vs. 1.18 nmol NPY+3 nmol MTII (FIG. 21B), 3 nmol MTII vs. acsf (FIG. 21C), and 100 nmol MTII vs. saline (FIG. 21D).

The hyperphagia in these models can be clearly seen by comparing the 12 hr food intake following a fast in vehicle-injected C57B/1/6J (2.4 g, FIG. 19A), C57B1/6J-A.sup.Y (3.7 g, FIG. 21A) and C57B1/6J-Lep.sup.ob (3.7 g. FIG. 21C) animals. As expected, MTII treatment inhibited food intake following a 16 hr fast in the C57B1/6J-A.sup.Y mouse (FIG. 21A; P<0.05). Interestingly, while food intake for the first four hours is significantly inhibited relative to vehicle-injected animals, it is also significantly less inhibited in the C57B1/6J-A.sup.Y animal than in the C57B/1/6J animal given the same 3 nmol dose (compare, FIG. 20A versus FIG. 21A, 1-4 hrs; P<0.001). The decreased effectiveness of the agonist in the presence of the A.sup.Y allele is consistent with the proposal that his allele results in chronic expression of agouti peptide melanocortin antagonist in the brain.

MTII, upon co-administration, also significantly inhibited the profound stimulation of feeding induced by neuropeptide Y (NPY), measured over a three hr period (FIG. 21C; P<0.005). Co-administration of an approximately two-fold molar excess of MTII produced a 74% inhibition of NPY-stimulated food intake at the three hour time point.

Finally, MTII also inhibited hyperphagia due to absence of leptin in the C57B1/6J-Lep.sup.ob mouse (FIG. 21C; P<0.001). MTII blocked feeding as potently (FIG. 20A), in contrast to the less potent inhibition described above for the C57B1/6J-A.sup.Y mouse.

The C57B/1/6J-Lep.sup.ob animal was also used to test the ability of MTII to regulate feeding when administered peripherally. Moderate doses (100 nmol) of MTII were inhibited feeding in the C57B1/6J-Lep.sup.ob mouse (P<0.001) while low doses (10 nmol) did not (date not shown). The kinetics were similar to those seen with ICV administration, with a potent inhibition of feeding for the first four hours. The 100-fold higher dose required peripherally, as well as the similar kinetics suggest a primarily central nervous system mechanism of action of MTII.

These data show that melanocortinergic neurons exert a tonic inhibition of feeding behavior, and that disruption of this signal leads to hyperphagia. With regard to the recently-discovered leptin hormone made by adipocytes, which is generally expressed at elevated levels in obese humans and rodents (such as the C57B1/6J-Lep.sup.ob animal), the regulatory defect is understood to be an incapacity to respond properly to the leptin hormone signal. The instant results indicate that the melanocortins act independently, or physiologically "downstream," from the leptin hormone/receptor interaction, because it has been shown herein that melanocortin receptor agonists can potently inhibit feeding in the C57B1/6J-Lep.sup.ob animal.

These results suggest that MC receptor agonists and antagonists can affect mammalian feeding behavior, and provide a means for determining candidate compounds for the development of effective pharmacological products directed towards alleviating such human ailments as obesity, anorexia and cachexia.

EXAMPLE 6

Use of MC Receptor-Expressing Recombinant Cells for Screening Compounds that Affect Feeding Behavior in Mammals

The results obtained in Example 6 indicated that cells expressing a variety of mammalian melanocortin receptors are useful for characterizing compounds as a first step towards developing MC receptor agonists and antagonists for controlling feeding behavior in mammals, particularly obesity and overweight disorders in general, as well as anorexia, cachexia and other failure-to-thrive disorders.

A panel of mammalian melanocortin receptor-expressing recombinant cells are provided as described above in Example 3, wherein each member of the panel comprises appropriate mammalian cells, such as human 293 cells, comprising a recombinant expression construct encoding the MC-1, MC-2 (ACTH), MC-3, MC-4 or MC-5 receptor, the panel constructed to comprise cells functionally expressing each of these MC receptor proteins.

The panel is used as follows. Receptor agonist activity is assayed by transient or stable expression of a protein which produces a metabolite reporter molecule in response to receptor binding by any of the MC receptor proteins. An example of such a reporter system is the recombinant expression construct described in Example 4, wherein cAMP responsive elements (CREs) are operatively linked to bacterially-derived .beta.-galactosidase (.beta.-gal) gene. In the event of receptor binding, cAMP is produced in the mammalian cell, and the CRE induces .beta.-gal expression. When co-incubated with a colorless substrate for .beta.-gal, receptor binding results in conversion of the colorless substrate to a blue-colored product, which can be easily scored visually or spectrophotometrically. Alternative reporter genes, such a luciferase, can also be used as reporter systems, provided that expression of the reporter molecule-producing protein is functionally linked to receptor binding of a test compound. Alternatively, cAMP production resulting from MC receptor binding can also be measured directly. Additionally, the cell panel or membranes from these cells can be used for direct radioligand binding assays.

Assay panels are arranged so that agonist activity can be identified, quantitated and correlated with expression of each MC receptor. Automated assays using such panels are also envisioned, whereby the qualitative and quantitative detection of a reporter metabolite is detected in an array (such as a 96-well tissue culture plate) and the data collected and assembled into a computer data-base or other analytical program.

Antagonist activity is detected by a modification of the above assay. In this assay, the inhibition of production of an amount of a known receptor agonist, specific for each receptor, is assayed in the presence of a putative antagonist compound. Production of metabolite reporter molecules and their qualitative and quantitative detection is achieved as described above, and the specificity and potency of each antagonist compound characterized with regard to the degree of inhibition achieved for each receptor.

In view of the instant disclosure, MC-3/MC-4 receptor antagonists are expected to be useful to inhibit food intake in a hungry animal, and MC-3/MC-4 receptor agonists are expected to be useful to increase food intake in an animal. Alternative patterns of feeding behavior associated with different patterns of MC receptor agonist/antagonist activity can be determined using this assay.

Compounds having agonist or antagonist activity with the MC-3 or MC-4 receptors detected using this assay are further screened in vivo to determine whether the observed receptor binding activity results in modification of feeding behavior when administered to an animal. In these assays, the MC receptor binding compounds detected using the assay are administered intracerebroventricularly as described above in Example 5 to animals after an overnight fast, to waking animals, or to animals that are not otherwise primed to be hungry. Feeding and locomotor activity is monitored in these animals, and compounds affecting eating behavior (either by inhibiting feeding in otherwise hungry animals or stimulating feeding in otherwise sated animals) are selected for further development.

In addition, systemic administration of compounds found to be active by ICV administration assays is used to screen such compounds for the ability to cross the blood-brain barrier. Such compounds are also useful as templates for modifications aimed at increasing the availability of these compounds in the brain after systemic administration, for increasing bioactivity, or both.

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.

__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 19- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 35 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..35#/function = "DegenerateRMATION: oligonucleot - #ide primer (sense)"#"The residue at positions 24 and 24 are inosine"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:# 35 SATY RCNNTKGACM GSTAC- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 32 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..32#/function = "DegenerateRMATION: oligonucleot - #ide primer (antisense)"#"The residue at position 18 is inosine"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:# 32 ANCC AGCAGASRYG AA- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1260 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA to mRNA- (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..14- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 15..959- (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 960..1260- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:- TTCCTGACAA GACT ATG TCC ACT CAG GAG CCC CAG A - #AG AGT CTT CTG GGT 50 Met S - #er Thr Gln Glu Pro Gln Lys Ser Leu Leu Gl - #y# 10- TCT CTC AAC TCC AAT GCC ACC TCT CAC CTT GG - #A CTG GCC ACC AAC CAG 98Ser Leu Asn Ser Asn Ala Thr Ser His Leu Gl - #y Leu Ala Thr Asn Gln# 25- TCA GAG CCT TGG TGC CTG TAT GTG TCC ATC CC - #A GAT GGC CTC TTC CTC 146Ser Glu Pro Trp Cys Leu Tyr Val Ser Ile Pr - #o Asp Gly Leu Phe Leu# 40- AGC CTA GGG CTG GTG AGT CTG GTG GAG AAT GT - #G CTG GTT GTG ATA GCC 194Ser Leu Gly Leu Val Ser Leu Val Glu Asn Va - #l Leu Val Val Ile Ala# 60- ATC ACC AAA AAC CGC AAC CTG CAC TCG CCC AT - #G TAT TAC TTC ATC TGC 242Ile Thr Lys Asn Arg Asn Leu His Ser Pro Me - #t Tyr Tyr Phe Ile Cys# 75- TGC CTG GCC CTG TCT GAC CTG ATG GTA AGT GT - #C AGC ATC GTG CTG GAG 290Cys Leu Ala Leu Ser Asp Leu Met Val Ser Va - #l Ser Ile Val Leu Glu# 90- ACT ACT ATC ATC CTG CTG CTG GAG GTG GGC AT - #C CTG GTG GCC AGA GTG 338Thr Thr Ile Ile Leu Leu Leu Glu Val Gly Il - #e Leu Val Ala Arg Val# 105- GCT TTG GTG CAG CAG CTG GAC AAC CTC ATT GA - #C GTG CTC ATC TGT GGC 386Ala Leu Val Gln Gln Leu Asp Asn Leu Ile As - #p Val Leu Ile Cys Gly# 120- TCC ATG GTG TCC AGT CTC TGC TTC CTG GGC AT - #C ATT GCT ATA GAC CGC 434Ser Met Val Ser Ser Leu Cys Phe Leu Gly Il - #e Ile Ala Ile Asp Arg125 1 - #30 1 - #35 1 -#40- TAC ATC TCC ATC TTC TAT GCG CTG CGT TAT CA - #C AGC ATC GTG ACG CTG 482Tyr Ile Ser Ile Phe Tyr Ala Leu Arg Tyr Hi - #s Ser Ile Val Thr Leu# 155- CCC AGA GCA CGA CGG GCT GTC GTG GGC ATC TG - #G ATG GTC AGC ATC GTC 530Pro Arg Ala Arg Arg Ala Val Val Gly Ile Tr - #p Met Val Ser Ile Val# 170- TCC AGC ACC CTC TTT ATC ACC TAC TAC AAG CA - #C ACA GCC GTT CTG CTC 578Ser Ser Thr Leu Phe Ile Thr Tyr Tyr Lys Hi - #s Thr Ala Val Leu Leu# 185- TGC CTC GTC ACT TTC TTT CTA GCC ATG CTG GC - #A CTC ATG GCG ATT CTG 626Cys Leu Val Thr Phe Phe Leu Ala Met Leu Al - #a Leu Met Ala Ile Leu# 200- TAT GCC CAC ATG TTC ACG AGA GCG TGC CAG CA - #C GTC CAG GGC ATT GCC 674Tyr Ala His Met Phe Thr Arg Ala Cys Gln Hi - #s Val Gln Gly Ile Ala205 2 - #10 2 - #15 2 -#20- CAG CTC CAC AAA AGG CGG CGG TCC ATC CGC CA - #A GGC TTC TGC CTC AAG 722Gln Leu His Lys Arg Arg Arg Ser Ile Arg Gl - #n Gly Phe Cys Leu Lys# 235- GGT GCT GCC ACC CTT ACT ATC CTT CTG GGG AT - #T TTC TTC CTG TGC TGG 770Gly Ala Ala Thr Leu Thr Ile Leu Leu Gly Il - #e Phe Phe Leu Cys Trp# 250- GGC CCC TTC TTC CTG CAT CTC TTG CTC ATC GT - #C CTC TGC CCT CAG CAC 818Gly Pro Phe Phe Leu His Leu Leu Leu Ile Va - #l Leu Cys Pro Gln His# 265- CCC ACC TGC AGC TGC ATC TTC AAG AAC TTC AA - #C CTC TTC CTC CTC CTC 866Pro Thr Cys Ser Cys Ile Phe Lys Asn Phe As - #n Leu Phe Leu Leu Leu# 280- ATC GTC CTC AGC TCC ACT GTT GAC CCC CTC AT - #C TAT GCT TTC CGC AGC 914Ile Val Leu Ser Ser Thr Val Asp Pro Leu Il - #e Tyr Ala Phe Arg Ser285 2 - #90 2 - #95 3 -#00- CAG GAG CTC CGC ATG ACA CTC AAG GAG GTG CT - #G CTG TGC TCC TGG 95 - #9Gln Glu Leu Arg Met Thr Leu Lys Glu Val Le - #u Leu Cys Ser Trp# 315- TGATCAGAGG GCGCTGGGCA GAGGGTGACA GTGATATCCA GTGGCCTGCA TC - #TGTGAGAC1019- CACAGGTACT CATCCCTTCC TGATCTCCAT TTGTCTAAGG GTCGACAGGA TG - #AGCTTTAA1079- AATAGAAACC CAGAGTGCCT GGGGCCAGGA GAAAGGGTAA CTGTGACTGC AG - #GGCTCACC1139- CAGGGCAGCT ACGGGAAGTG GAGGAGACAG GGATGGGAAC TCTAGCCCTG AG - #CAAGGGTC1199- AGACCACAGG CTCCTGAAGA GCTTCACCTC TCCCCACCTA CAGGCAACTC CT - #GCTCAAGC1259# 1260- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 315 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:- Met Ser Thr Gln Glu Pro Gln Lys Ser Leu Le - #u Gly Ser Leu Asn Ser# 15- Asn Ala Thr Ser His Leu Gly Leu Ala Thr As - #n Gln Ser Glu Pro Trp# 30- Cys Leu Tyr Val Ser Ile Pro Asp Gly Leu Ph - #e Leu Ser Leu Gly Leu# 45- Val Ser Leu Val Glu Asn Val Leu Val Val Il - #e Ala Ile Thr Lys Asn# 60- Arg Asn Leu His Ser Pro Met Tyr Tyr Phe Il - #e Cys Cys Leu Ala Leu# 80- Ser Asp Leu Met Val Ser Val Ser Ile Val Le - #u Glu Thr Thr Ile Ile# 95- Leu Leu Leu Glu Val Gly Ile Leu Val Ala Ar - #g Val Ala Leu Val Gln# 110- Gln Leu Asp Asn Leu Ile Asp Val Leu Ile Cy - #s Gly Ser Met Val Ser# 125- Ser Leu Cys Phe Leu Gly Ile Ile Ala Ile As - #p Arg Tyr Ile Ser Ile# 140- Phe Tyr Ala Leu Arg Tyr His Ser Ile Val Th - #r Leu Pro Arg Ala Arg145 1 - #50 1 - #55 1 -#60- Arg Ala Val Val Gly Ile Trp Met Val Ser Il - #e Val Ser Ser Thr Leu# 175- Phe Ile Thr Tyr Tyr Lys His Thr Ala Val Le - #u Leu Cys Leu Val Thr# 190- Phe Phe Leu Ala Met Leu Ala Leu Met Ala Il - #e Leu Tyr Ala His Met# 205- Phe Thr Arg Ala Cys Gln His Val Gln Gly Il - #e Ala Gln Leu His Lys# 220- Arg Arg Arg Ser Ile Arg Gln Gly Phe Cys Le - #u Lys Gly Ala Ala Thr225 2 - #30 2 - #35 2 -#40- Leu Thr Ile Leu Leu Gly Ile Phe Phe Leu Cy - #s Trp Gly Pro Phe Phe# 255- Leu His Leu Leu Leu Ile Val Leu Cys Pro Gl - #n His Pro Thr Cys Ser# 270- Cys Ile Phe Lys Asn Phe Asn Leu Phe Leu Le - #u Leu Ile Val Leu Ser# 285- Ser Thr Val Asp Pro Leu Ile Tyr Ala Phe Ar - #g Ser Gln Glu Leu Arg# 300- Met Thr Leu Lys Glu Val Leu Leu Cys Ser Tr - #p305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1633 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA to mRNA- (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..461- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 462..1415- (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1416..1633- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:- CCCGCATGTG GCCGCCCTCA ATGGAGGGCT CTGAGAACGA CTTTTAAAAC GC - #AGAGAAAA 60- AGCTCCATTC TTCCCAGACC TCAGCGCAGC CCTGGCCCAG GAAGGGAGGA GA - #CAGAGGCC 120- AGGACGGTCC AGAGGTGTCG AAATGTCCTG GGAACCTGAG CAGCAGCCAC CA - #GGGAAGAG 180- GCAGGGAGGG AGCTGAGGAC CAGGCTTGGT TGTGAGAATC CCTGAGCCCA GG - #CGGTTGAT 240- GCCAGGAGGT GTCTGGACTG GCTGGGCCAT GCCTGGGCTG ACCTGTCCAG CC - #AGGGAGAG 300- GGTGTGAGGG CAGATCTGGG GGTGCCCAGA TGGAAGGAGG CAGGCATGGG GA - #CACCCAAG 360- GCCCCCTGGC AGCACCATGA ACTAAGCAGG ACACCTGGAG GGGAAGAACT GT - #GGGGACCT 420#GTG CAG 473TCCT TCCTGCTTCC TGGACAGGAC T ATG GCT# Met Ala Val Gln# 1- GGA TCC CAG AGA AGA CTT CTG GGC TCC CTC AA - #C TCC ACC CCC ACA GCC 521Gly Ser Gln Arg Arg Leu Leu Gly Ser Leu As - #n Ser Thr Pro Thr Ala# 20- ATC CCC CAG CTG GGG CTG GCT GCC AAC CAG AC - #A GGA GCC CGG TGC CTG 569Ile Pro Gln Leu Gly Leu Ala Ala Asn Gln Th - #r Gly Ala Arg Cys Leu# 35- GAG GTG TCC ATC TCT GAC GGG CTC TTC CTC AG - #C CTG GGG CTG GTG AGC 617Glu Val Ser Ile Ser Asp Gly Leu Phe Leu Se - #r Leu Gly Leu Val Ser# 50- TTG GTG GAG AAC GCG CTG GTG GTG GCC ACC AT - #C GCC AAG AAC CGG AAC 665Leu Val Glu Asn Ala Leu Val Val Ala Thr Il - #e Ala Lys Asn Arg Asn# 65- CTG CAC TCA CCC ATG TAC TGC TTC ATC TGC TG - #C CTG GCC TTG TCG GAC 713Leu His Ser Pro Met Tyr Cys Phe Ile Cys Cy - #s Leu Ala Leu Ser Asp# 80- CTG CTG GTG AGC GGG ACG AAC GTG CTG GAG AC - #G GCC GTC ATC CTC CTG 761Leu Leu Val Ser Gly Thr Asn Val Leu Glu Th - #r Ala Val Ile Leu Leu#100- CTG GAG GCC GGT GCA CTG GTG GCC CGG GCT GC - #G GTG CTG CAG CAG CTG 809Leu Glu Ala Gly Ala Leu Val Ala Arg Ala Al - #a Val Leu Gln Gln Leu# 115- GAC AAT GTC ATT GAC GTG ATC ACC TGC AGC TC - #C ATG CTG TCC AGC CTC 857Asp Asn Val Ile Asp Val Ile Thr Cys Ser Se - #r Met Leu Ser Ser Leu# 130- TGC TTC CTG GGC GCC ATC GCC GTG GAC CGC TA - #C ATC TCC ATC TTC TAC 905Cys Phe Leu Gly Ala Ile Ala Val Asp Arg Ty - #r Ile Ser Ile Phe Tyr# 145- GCA CTG CGC TAC CAC AGC ATC GTG ACC CTG CC - #G CGG GCG CCG CGA GCC 953Ala Leu Arg Tyr His Ser Ile Val Thr Leu Pr - #o Arg Ala Pro Arg Ala# 160- GTT GCG GCC ATC TGG GTG GCC AGT GTC GTC TT - #C AGC ACG CTC TTC ATC1001Val Ala Ala Ile Trp Val Ala Ser Val Val Ph - #e Ser Thr Leu Phe Ile165 1 - #70 1 - #75 1 -#80- GGC TAC TAC GAC CAC GTG GCC GTC CTG CTG TG - #C CTC GTG GTC TTC TTC1049Gly Tyr Tyr Asp His Val Ala Val Leu Leu Cy - #s Leu Val Val Phe Phe# 195- CTG GCT ATG CTG GTG CTC ATG GCC GTG CTG GA - #C GTC CAC ATG CTG GCC1097Leu Ala Met Leu Val Leu Met Ala Val Leu As - #p Val His Met Leu Ala# 210- CGG GCC TGC CAG CAC GCC CAG GGC ATC GCC CG - #G CTC CAC AAG AGG CAG1145Arg Ala Cys Gln His Ala Gln Gly Ile Ala Ar - #g Leu His Lys Arg Gln# 225- CGC CCG GTC CAC CAG GGC TTT GGC CTT AAA GG - #C GCT GTC ACC CTC ACC1193Arg Pro Val His Gln Gly Phe Gly Leu Lys Gl - #y Ala Val Thr Leu Thr# 240- ATC CTG CTG GGC ATT TTC TTC CTC TGC TGG GG - #C CCC TTC TTC CTG CAT1241Ile Leu Leu Gly Ile Phe Phe Leu Cys Trp Gl - #y Pro Phe Phe Leu His245 2 - #50 2 - #55 2 -#60- CTC ACA CTC ATC GTC CTC TGC CCC GAG CAC CC - #C ACG TGC GGC TGC ATC1289Leu Thr Leu Ile Val Leu Cys Pro Glu His Pr - #o Thr Cys Gly Cys Ile# 275- TTC AAG AAC TTC AAC CTC TTT CTC GCC CTC AT - #C ATC TGC AAT GCC ATC1337Phe Lys Asn Phe Asn Leu Phe Leu Ala Leu Il - #e Ile Cys Asn Ala Ile# 290- ATC GAC CCC CTC ATC TAC GCC TTC CAC AGC CA - #G GAG CTC CGC AGG ACG1385Ile Asp Pro Leu Ile Tyr Ala Phe His Ser Gl - #n Glu Leu Arg Arg Thr# 305- CTC AAG GAG GTG CTG ACA TGC TCC TGG TGA GC - #GCGGTGCA CGCGCTTTAA1435Leu Lys Glu Val Leu Thr Cys Ser Trp *# 315- GTGTGCTGGG CAGAGGGAGG TGGTGATATT GTGGTCTGGT TCCTGTGTGA CC - #CTGGGCAG1495- TTCCTTACCT CCCTGGTCCC CGTTTGTCAA AGAGGATGGA CTAAATGATC TC - #TGAAAGTG1555- TTGAAGCGCG GACCCTTCTG GGCAGGGAGG GGTCCTGCAA AACTCCAGGC AG - #GACTTCTC1615#1633 AC- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 ami - #no acids (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:- Met Ala Val Gln Gly Ser Gln Arg Arg Leu Le - #u Gly Ser Leu Asn Ser# 15- Thr Pro Thr Ala Ile Pro Gln Leu Gly Leu Al - #a Ala Asn Gln Thr Gly# 30- Ala Arg Cys Leu Glu Val Ser Ile Ser Asp Gl - #y Leu Phe Leu Ser Leu# 45- Gly Leu Val Ser Leu Val Glu Asn Ala Leu Va - #l Val Ala Thr Ile Ala# 60- Lys Asn Arg Asn Leu His Ser Pro Met Tyr Cy - #s Phe Ile Cys Cys Leu# 80- Ala Leu Ser Asp Leu Leu Val Ser Gly Thr As - #n Val Leu Glu Thr Ala# 95- Val Ile Leu Leu Leu Glu Ala Gly Ala Leu Va - #l Ala Arg Ala Ala Val# 110- Leu Gln Gln Leu Asp Asn Val Ile Asp Val Il - #e Thr Cys Ser Ser Met# 125- Leu Ser Ser Leu Cys Phe Leu Gly Ala Ile Al - #a Val Asp Arg Tyr Ile# 140- Ser Ile Phe Tyr Ala Leu Arg Tyr His Ser Il - #e Val Thr Leu Pro Arg145 1 - #50 1 - #55 1 -#60- Ala Pro Arg Ala Val Ala Ala Ile Trp Val Al - #a Ser Val Val Phe Ser# 175- Thr Leu Phe Ile Gly Tyr Tyr Asp His Val Al - #a Val Leu Leu Cys Leu# 190- Val Val Phe Phe Leu Ala Met Leu Val Leu Me - #t Ala Val Leu Asp Val# 205- His Met Leu Ala Arg Ala Cys Gln His Ala Gl - #n Gly Ile Ala Arg Leu# 220- His Lys Arg Gln Arg Pro Val His Gln Gly Ph - #e Gly Leu Lys Gly Ala225 2 - #30 2 - #35 2 -#40- Val Thr Leu Thr Ile Leu Leu Gly Ile Phe Ph - #e Leu Cys Trp Gly Pro# 255- Phe Phe Leu His Leu Thr Leu Ile Val Leu Cy - #s Pro Glu His Pro Thr# 270- Cys Gly Cys Ile Phe Lys Asn Phe Asn Leu Ph - #e Leu Ala Leu Ile Ile# 285- Cys Asn Ala Ile Ile Asp Pro Leu Ile Tyr Al - #a Phe His Ser Gln Glu# 300- Leu Arg Arg Thr Leu Lys Glu Val Leu Thr Cy - #s Ser Trp305 3 - #10 3 - #15- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 2012 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA to mRNA- (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..693- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 694..1587- (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1588..2012- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:- ACAACACTTT ATATATATTT TTATAAATGT AAGGGGTACA AAGGTGCCAT TT - #TGTTACAT 60- GGATATACCG TGTAGTGGTG AAGCCTGGGC TTTTAGTGTA TCTGTCATCA GA - #ATAACATA 120- CGTGTTACCC ATAGGAATTT CTCATCACCC GCCCCCTCCA CCCTTCGAGT CT - #CCAATGTC 180- CATTCCACAC TCTATATCCA CGTGTATGCA TATAGCTCCA CATATAAGTG AG - #AACATGTA 240- GTATTTGACT TCCTCTTTCT GAGTTATTTC ACTTTGATAA TGGCCTCCAC TT - #CCATCCAT 300- GTTGCTGCAA AAGACATGAC CTTATTCTTT TTGATAGCTG GGGAGTACTC CA - #TTGTGTAT 360- ATGTACCACA TTTCTTTATC CATTCACCCA TTGAGAACAC TTAGTTGATT CC - #ATATCTTT 420- GCTATTGTCA CTAGTGCTGC AATAAACATA CATGTGCAGG CTCCTTCTAA TA - #TACTGATT 480- TATATTTTAT GGAGAGAGAT AGAGTTCTTA GCGAGTGTGC TGTTTATTTC TA - #GTGTACTT 540- GCAACTAATA TTCTGTATAC TCCCTTTAGG TGATTGGAGA TTTAACTTAG AT - #CTCCAGCA 600- AGTGCTACAA GAAGAAAAGA TCCTGAAGAA TCAATCAAGT TTCCGTGAAG TC - #AAGTCCAA 660- GTAACATCCC CGCCTTAACC ACAAGCAGGA GAA ATG AAG CAC AT - #T ATC AAC TCG 714# Met Lys His Ile Ile Asn Ser#5 1- TAT GAA AAC ATC AAC AAC ACA GCA AGA AAT AA - #T TCC GAC TGT CCT CGT 762Tyr Glu Asn Ile Asn Asn Thr Ala Arg Asn As - #n Ser Asp Cys Pro Arg# 20- TGT GTT TTG CCG GAG GAG ATA TTT TTC ACA AT - #T TCC ATT GTT GGA GTT 810Cys Val Leu Pro Glu Glu Ile Phe Phe Thr Il - #e Ser Ile Val Gly Val# 35- TTG GAG AAT CTG ATC GTC CTG CTG GCT GTG TT - #C AAG AAT AAG AAT CTC 858Leu Glu Asn Leu Ile Val Leu Leu Ala Val Ph - #e Lys Asn Lys Asn Leu# 55- CAG GCA CCC ATG TAC TTT TTC ATC TGT AGC TT - #G GCC ATA TCT GAT ATG 906Gln Ala Pro Met Tyr Phe Phe Ile Cys Ser Le - #u Ala Ile Ser Asp Met# 70- CTG GGC AGC CTA TAT AAG ATC TTG GAA AAT AT - #C CTG ATC ATA TTG AGA 954Leu Gly Ser Leu Tyr Lys Ile Leu Glu Asn Il - #e Leu Ile Ile Leu Arg# 85- AAC ATG GGC ATA CTC AAG CCA CGT GGC AGT TT - #T GAA ACC ACA GCC CAT1002Asn Met Gly Ile Leu Lys Pro Arg Gly Ser Ph - #e Glu Thr Thr Ala His# 100- GAC ATC ATC GAC TCC CTG TTT CTG CTC TCC CG - #T CTT GGC TCC ATC TTC1050Asp Ile Ile Asp Ser Leu Phe Leu Leu Ser Ar - #g Leu Gly Ser Ile Phe# 115- GAC CTG CTC GTG ATT GCT GCG GAC CGC TAC AT - #C ACC ATC TTC CAC GCA1098Asp Leu Leu Val Ile Ala Ala Asp Arg Tyr Il - #e Thr Ile Phe His Ala120 1 - #25 1 - #30 1 -#35- CTG CGG TAC CAC AGC ATC GTG ACC ATG CGC CG - #C ACT GTG GTG GTG CTT1146Leu Arg Tyr His Ser Ile Val Thr Met Arg Ar - #g Thr Val Val Val Leu# 150- ACG GTC ATC TGG ACG TTC TGC ACG GGG ACT GG - #C ATC ACC ATG GTG ATC1194Thr Val Ile Trp Thr Phe Cys Thr Gly Thr Gl - #y Ile Thr Met Val Ile# 165- TTC TCC CAT CAT GTG CCC CAC GTG ATC ACC TT - #C ACG TCG CTG TTC CCG1242Phe Ser His His Val Pro His Val Ile Thr Ph - #e Thr Ser Leu Phe Pro# 180- CTG ATG CTG GTC TTC ATC CTG TGC CTC TAT GT - #G CAC ATG TTC CTG CTG1290Leu Met Leu Val Phe Ile Leu Cys Leu Tyr Va - #l His Met Phe Leu Leu# 195- GCT CGA TGG CAC ACC AGG AAG ATC TCC ACC CT - #C CCC AGA GCC AAC ATG1338Ala Arg Trp His Thr Arg Lys Ile Ser Thr Le - #u Pro Arg Ala Asn Met200 2 - #05 2 - #10 2 -#15- AAA GGG GCC ATG ACA CTG ACC ATC CTG CTC GG - #G GTC TTC ATC TTC TGC1386Lys Gly Ala Met Thr Leu Thr Ile Leu Leu Gl - #y Val Phe Ile Phe Cys# 230- TGG GCC CCC TTT GTG CTT CAT GTC CTC TTG AT - #G ACA TTC TGC CCA AGT1434Trp Ala Pro Phe Val Leu His Val Leu Leu Me - #t Thr Phe Cys Pro Ser# 245- AAC CCC TAC TGC GCC TGC TAC ATG TCT CTC TT - #C CAG GTG AAC GGC ATG1482Asn Pro Tyr Cys Ala Cys Tyr Met Ser Leu Ph - #e Gln Val Asn Gly Met# 260- TTG ATC ATG TGC AAT GCC GTC ATT GAC CCC TT - #C ATA TAT GCC TTC CGG1530Leu Ile Met Cys Asn Ala Val Ile Asp Pro Ph - #e Ile Tyr Ala Phe Arg# 275- AGC CCA GAG CTC AGG GAC GCA TTC AAA AAG AT - #G ATC TTC TGC AGC AGG1578Ser Pro Glu Leu Arg Asp Ala Phe Lys Lys Me - #t Ile Phe Cys Ser Arg280 2 - #85 2 - #90 2 -#95- TAC TGG TAG AATGGCTGAT CCCTGGTTTT AGAATCCATG GGAATAACG - #T1627Tyr Trp *- TGCCAAGTGC CAGAATAGTG TAACATTCCA ACAAATGCCA GTGCTCCTCA CT - #GGCCTTCC1687- TTCCCTAATG GATGCAAGGA TGACCCACCA GCTAGTGTTT CTGAATACTA TG - #GCCAGGAA1747- CAGTCTATTG TAGGGGCAAC TCTATTTGTG ACTGGACAGA TAAAACGTGT AG - #TAAAAGAA1807- GGATAGAATA CAAAGTATTA GGTACAAAAG TAATTAGGTT TGCATTACTT AT - #GACAAATG1867- CATTACTTTT GCACCAATCT AGTAAAACAG CAATAAAAAT TCAAGGGCTT TG - #GGCTAAGG1927- CAAAGACTTG CTTTCCTGTG GACATTAACA AGCCAGTTCT GAGGCGGCCT TT - #CCAGGTGG1987# 2012 TTTC AGAGT- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 297 ami - #no acids (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:- Met Lys His Ile Ile Asn Ser Tyr Glu Asn Il - #e Asn Asn Thr Ala Arg# 15- Asn Asn Ser Asp Cys Pro Arg Cys Val Leu Pr - #o Glu Glu Ile Phe Phe# 30- Thr Ile Ser Ile Val Gly Val Leu Glu Asn Le - #u Ile Val Leu Leu Ala# 45- Val Phe Lys Asn Lys Asn Leu Gln Ala Pro Me - #t Tyr Phe Phe Ile Cys# 60- Ser Leu Ala Ile Ser Asp Met Leu Gly Ser Le - #u Tyr Lys Ile Leu Glu# 80- Asn Ile Leu Ile Ile Leu Arg Asn Met Gly Il - #e Leu Lys Pro Arg Gly# 95- Ser Phe Glu Thr Thr Ala His Asp Ile Ile As - #p Ser Leu Phe Leu Leu# 110- Ser Arg Leu Gly Ser Ile Phe Asp Leu Leu Va - #l Ile Ala Ala Asp Arg# 125- Tyr Ile Thr Ile Phe His Ala Leu Arg Tyr Hi - #s Ser Ile Val Thr Met# 140- Arg Arg Thr Val Val Val Leu Thr Val Ile Tr - #p Thr Phe Cys Thr Gly145 1 - #50 1 - #55 1 -#60- Thr Gly Ile Thr Met Val Ile Phe Ser His Hi - #s Val Pro His Val Ile# 175- Thr Phe Thr Ser Leu Phe Pro Leu Met Leu Va - #l Phe Ile Leu Cys Leu# 190- Tyr Val His Met Phe Leu Leu Ala Arg Trp Hi - #s Thr Arg Lys Ile Ser# 205- Thr Leu Pro Arg Ala Asn Met Lys Gly Ala Me - #t Thr Leu Thr Ile Leu# 220- Leu Gly Val Phe Ile Phe Cys Trp Ala Pro Ph - #e Val Leu His Val Leu225 2 - #30 2 - #35 2 -#40- Leu Met Thr Phe Cys Pro Ser Asn Pro Tyr Cy - #s Ala Cys Tyr Met Ser# 255- Leu Phe Gln Val Asn Gly Met Leu Ile Met Cy - #s Asn Ala Val Ile Asp# 270- Pro Phe Ile Tyr Ala Phe Arg Ser Pro Glu Le - #u Arg Asp Ala Phe Lys# 285- Lys Met Ile Phe Cys Ser Arg Tyr Trp# 295- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1108 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA to mRNA- (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..132- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 133..1026- (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1027..1106- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:- GGGGCCAGAA AGTTCCTGCT TCAGAGCAGA AGATCTTCAG CAAGAACTAC AA - #AGAAGAAA 60- AGATTCTGGA GAATCAATCA AGTTTCCTGT CAAGTTCCAG TAACGTTTCT GT - #CTTAACTG 120- CACACAGGAA AG ATG AAA CAC ATT CTC AAT CTG TAT - # GAA AAC CTC AAC 168 Met Lys Hi - #s Ile Leu Asn Leu Tyr Glu Asn Leu Asn# 10- AGT ACA GCA AGA AAT AAC TCA GAC TGT CCT GC - #T GTG ATT TTG CCA GAA 216Ser Thr Ala Arg Asn Asn Ser Asp Cys Pro Al - #a Val Ile Leu Pro Glu# 25- GAG ATA TTT TTC ACA GTA TCC ATT GTT GGG GT - #T TTG GAG AAC CTG ATG 264Glu Ile Phe Phe Thr Val Ser Ile Val Gly Va - #l Leu Glu Asn Leu Met# 40- GTC CTT CTG GCT GTG GCC AAG AAT AAG ATG CT - #T CAG TCG CCC ATG TAC 312Val Leu Leu Ala Val Ala Lys Asn Lys Met Le - #u Gln Ser Pro Met Tyr# 60- TTT TTC ATC TGC AGC TTG GCT ATT TCC GAT AT - #G CTG GGG AGC ATG TAC 360Phe Phe Ile Cys Ser Leu Ala Ile Ser Asp Me - #t Leu Gly Ser Met Tyr# 75- AAG ATT TTG GAA AAC GTT CTG ATC ATG TTC AA - #A AAC ATG GGT TAC CTC 408Lys Ile Leu Glu Asn Val Leu Ile Met Phe Ly - #s Asn Met Gly Tyr Leu# 90- GAG CCT CGA GGC AGT TTT GAA AGC ACA GCA GA - #T GAT GTG GTG GAC TCC 456Glu Pro Arg Gly Ser Phe Glu Ser Thr Ala As - #p Asp Val Val Asp Ser# 105- CTG TTC ATC CTC TCC CTT CTC GGC TCC ATC TG - #C AGC CTG TCT GTG ATT 504Leu Phe Ile Leu Ser Leu Leu Gly Ser Ile Cy - #s Ser Leu Ser Val Ile# 120- GCC GCT GAC CGC TAC ACT ACA ATC TTC CAC GC - #T CTG CAG TAC CAC CGC 552Ala Ala Asp Arg Tyr Thr Thr Ile Phe His Al - #a Leu Gln Tyr His Arg125 1 - #30 1 - #35 1 -#40- ATC ATG ACC CCC GCA CCG TGC CCT CGT CAT CT - #G ACG GTC CTC TGG CGA 600Ile Met Thr Pro Ala Pro Cys Pro Arg His Le - #u Thr Val Leu Trp Arg# 155- GGC TGC ACA GGC AGT GGC ATT ACC ATC GTG AC - #C TTC TCC CAT CAC GTC 648Gly Cys Thr Gly Ser Gly Ile Thr Ile Val Th - #r Phe Ser His His Val# 170- CCC ACA GTG ATC GCC TTC ACA GCG CTG TTC CC - #G CTG ATG CTG GCC TTC 696Pro Thr Val Ile Ala Phe Thr Ala Leu Phe Pr - #o Leu Met Leu Ala Phe# 185- ATC CTG TGC CTC TAC GTG CAC ATG TTC CTG CT - #G GCC CGC TCC CAC ACC 744Ile Leu Cys Leu Tyr Val His Met Phe Leu Le - #u Ala Arg Ser His Thr# 200- AGG AGG ACC CCC TCC CTT CCC AAA GCC AAC AT - #G AGA GGG GCC GTC ACA 792Arg Arg Thr Pro Ser Leu Pro Lys Ala Asn Me - #t Arg Gly Ala Val Thr205 2 - #10 2 - #15 2 -#20- CTG ACT GTC CTG CTC GGG GTC TTC ATT TTC TG - #T TGG GCA CCC TTT GTC 840Leu Thr Val Leu Leu Gly Val Phe Ile Phe Cy - #s Trp Ala Pro Phe Val# 235- CTT CAT GTC CTC TTG ATG ACA TTC TGC CCA GC - #T GAC CCC TAC TGT GCC 888Leu His Val Leu Leu Met Thr Phe Cys Pro Al - #a Asp Pro Tyr Cys Ala# 250- TGC TAC ATG TCC CTC TTC CAG GTG AAT GGT GT - #G TTG ATC ATG TGT AAT 936Cys Tyr Met Ser Leu Phe Gln Val Asn Gly Va - #l Leu Ile Met Cys Asn# 265- GCC ATC ATC GAC CCC TTC ATA TAT GCC TTT CG - #G AGC CCA GAG CTC AGG 984Ala Ile Ile Asp Pro Phe Ile Tyr Ala Phe Ar - #g Ser Pro Glu Leu Arg# 280- GTC GCA TTC AAA AAG ATG GTT ATC TGC AAC TG - #T TAC CAG TAG#1026Val Ala Phe Lys Lys Met Val Ile Cys Asn Cy - #s Tyr Gln *285 2 - #90 2 - #95- AATGATTGGT CCCTGATTTT AGGAGCCACA GGGATATACT GTCAGGGACA GA - #GTAGCGTG1086# 1108GGA CT- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 297 ami - #no acids (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:- Met Lys His Ile Leu Asn Leu Tyr Glu Asn Le - #u Asn Ser Thr Ala Arg# 15- Asn Asn Ser Asp Cys Pro Ala Val Ile Leu Pr - #o Glu Glu Ile Phe Phe# 30- Thr Val Ser Ile Val Gly Val Leu Glu Asn Le - #u Met Val Leu Leu Ala# 45- Val Ala Lys Asn Lys Met Leu Gln Ser Pro Me - #t Tyr Phe Phe Ile Cys# 60- Ser Leu Ala Ile Ser Asp Met Leu Gly Ser Me - #t Tyr Lys Ile Leu Glu# 80- Asn Val Leu Ile Met Phe Lys Asn Met Gly Ty - #r Leu Glu Pro Arg Gly# 95- Ser Phe Glu Ser Thr Ala Asp Asp Val Val As - #p Ser Leu Phe Ile Leu# 110- Ser Leu Leu Gly Ser Ile Cys Ser Leu Ser Va - #l Ile Ala Ala Asp Arg# 125- Tyr Thr Thr Ile Phe His Ala Leu Gln Tyr Hi - #s Arg Ile Met Thr Pro# 140- Ala Pro Cys Pro Arg His Leu Thr Val Leu Tr - #p Arg Gly Cys Thr Gly145 1 - #50 1 - #55 1 -#60- Ser Gly Ile Thr Ile Val Thr Phe Ser His Hi - #s Val Pro Thr Val Ile# 175- Ala Phe Thr Ala Leu Phe Pro Leu Met Leu Al - #a Phe Ile Leu Cys Leu# 190- Tyr Val His Met Phe Leu Leu Ala Arg Ser Hi - #s Thr Arg Arg Thr Pro# 205- Ser Leu Pro Lys Ala Asn Met Arg Gly Ala Va - #l Thr Leu Thr Val Leu# 220- Leu Gly Val Phe Ile Phe Cys Trp Ala Pro Ph - #e Val Leu His Val Leu225 2 - #30 2 - #35 2 -#40- Leu Met Thr Phe Cys Pro Ala Asp Pro Tyr Cy - #s Ala Cys Tyr Met Ser# 255- Leu Phe Gln Val Asn Gly Val Leu Ile Met Cy - #s Asn Ala Ile Ile Asp# 270- Pro Phe Ile Tyr Ala Phe Arg Ser Pro Glu Le - #u Arg Val Ala Phe Lys# 285- Lys Met Val Ile Cys Asn Cys Tyr Gln# 295- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1338 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA to mRNA- (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..297- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 298..1269- (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1270..1338- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:- GGCTGTAACT GTAGCAACCG GTGTTGGGTG GGGATGAGAA GAGACCAGAG AG - #AGAGAGGG 60- TCAGAGCGAC AGGGGATGAG ACAGGCTGGT CAGAGTCTGC ACTGATTGTT GG - #AGACGCAA 120- AGGAAAGTTT TTTCTATGTC TCCAACCTCC CCCTCCTCCC CCGTTTCTCT CT - #GGAGAAAC 180- TAAAATGTAG ACTGGACAGC ATCCACAAGA GAAGCACCTA GAAGAAGATT TT - #TTTTTCCC 240- AGCAGCTTGC TCAGGACCCT GCAGGAGCTG CAGCCGGAAC TGGTCCCGCC GA - #TAACC 297- ATG AAC TCT TCC TGC TGC CCG TCC TCC TCT TA - #T CCG ACG CTG CCT AAC 345Met Asn Ser Ser Cys Cys Pro Ser Ser Ser Ty - #r Pro Thr Leu Pro Asn# 15- CTC TCC CAG CAC CCT GCA GCC CCC TCT GCC AG - #C AAC CGG AGT GGC AGT 393Leu Ser Gln His Pro Ala Ala Pro Ser Ala Se - #r Asn Arg Ser Gly Ser# 30- GGG TTC TGC GAG CAG GTT TTC ATC AAG CCA GA - #G GTC TTC CTG GCA CTG 441Gly Phe Cys Glu Gln Val Phe Ile Lys Pro Gl - #u Val Phe Leu Ala Leu# 45- GGC ATC GTC AGT CTG ATG GAA AAC ATC CTG GT - #G ATC CTG GCT GTG GTG 489Gly Ile Val Ser Leu Met Glu Asn Ile Leu Va - #l Ile Leu Ala Val Val# 60- AGG AAC GGC AAC CTG CAC TCC CCC ATG TAC TT - #C TTC CTG CTG AGC CTG 537Arg Asn Gly Asn Leu His Ser Pro Met Tyr Ph - #e Phe Leu Leu Ser Leu# 80- CTG CAG GCC GAC CTG CTG GTG AGC CTG TCC AA - #C TCC CTG GAG ACC ATC 585Leu Gln Ala Asp Leu Leu Val Ser Leu Ser As - #n Ser Leu Glu Thr Ile# 95- ATG ATC GTG GTT ATC AAC AGC GAC TCC CTG AC - #C TTG GAG GAC CAA TTC 633Met Ile Val Val Ile Asn Ser Asp Ser Leu Th - #r Leu Glu Asp Gln Phe# 110- ATC CAG CAC ATG GAC AAC ATC TTC GAC TCT AT - #G ATC TGC ATC TCC CTG 681Ile Gln His Met Asp Asn Ile Phe Asp Ser Me - #t Ile Cys Ile Ser Leu# 125- GTG GCC TCC ATC TGC AAC CTC CTG GCC ATC GC - #C GTG GAC AGG TAC GTC 729Val Ala Ser Ile Cys Asn Leu Leu Ala Ile Al - #a Val Asp Arg Tyr Val# 140- ACC ATC TTC TAT GCC CTC CGT TAC CAC AGC AT - #C ATG ACG GTT AGG AAA 777Thr Ile Phe Tyr Ala Leu Arg Tyr His Ser Il - #e Met Thr Val Arg Lys145 1 - #50 1 - #55 1 -#60- GCC CTC TCC TTG ATC GTG GCC ATC TGG GTC TG - #C TGT GGC ATC TGC GGC 825Ala Leu Ser Leu Ile Val Ala Ile Trp Val Cy - #s Cys Gly Ile Cys Gly# 175- GTG ATG TTC ATC GTC TAC TCC GAG AGC AAG AT - #G GTC ATC GTG TGC CTC 873Val Met Phe Ile Val Tyr Ser Glu Ser Lys Me - #t Val Ile Val Cys Leu# 190- ATC ACC ATG TTC TTC GCC ATG GTG CTC CTC AT - #G GGC ACC CTG TAC ATC 921Ile Thr Met Phe Phe Ala Met Val Leu Leu Me - #t Gly Thr Leu Tyr Ile# 205- CAC ATG TTC CTC TTC GCC AGG CTG CAC GTC CA - #G CGC ATC GCG GCA CTG 969His Met Phe Leu Phe Ala Arg Leu His Val Gl - #n Arg Ile Ala Ala Leu# 220- CCA CCT GCT GAC GGG CTA GCC CCG CAG CAG CA - #C TCG TGC ATG AAG GGG1017Pro Pro Ala Asp Gly Leu Ala Pro Gln Gln Hi - #s Ser Cys Met Lys Gly225 2 - #30 2 - #35 2 -#40- GCC GTC ACC ATC ACC ATC CTG CTG GGG GTT TT - #C ATC TTC TGC TGG GCG1065Ala Val Thr Ile Thr Ile Leu Leu Gly Val Ph - #e Ile Phe Cys Trp Ala# 255- CCT TTC TTC CTC CAC CTG GTC CTC ATC ATC AC - #C TGC CCC ACC AAC CCC1113Pro Phe Phe Leu His Leu Val Leu Ile Ile Th - #r Cys Pro Thr Asn Pro# 270- TAC TGC ATC TGC TAC ACG GCG CAC TTC AAC AC - #C TAC CTG GTT CTC ATC1161Tyr Cys Ile Cys Tyr Thr Ala His Phe Asn Th - #r Tyr Leu Val Leu Ile# 285- ATG TGC AAC TCT GTC ATC GAC CCC CTC ATC TA - #C GCC TTC CGC AGC CTG1209Met Cys Asn Ser Val Ile Asp Pro Leu Ile Ty - #r Ala Phe Arg Ser Leu# 300- GAG CTG CGA AAC ACC TTC AAG GAG ATT CTC TG - #C GGT TGC AAT GGC ATG1257Glu Leu Arg Asn Thr Phe Lys Glu Ile Leu Cy - #s Gly Cys Asn Gly Met305 3 - #10 3 - #15 3 -#20- AAC GTG GGC TAG GAACCCCCGA GGAGGTGTTC CACGGCTAGC CA - #AGAGAGAA1309Asn Val Gly *# 1338 AGAC ACAGAAGGG- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 323 ami - #no acids (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:- Met Asn Ser Ser Cys Cys Pro Ser Ser Ser Ty - #r Pro Thr Leu Pro Asn# 15- Leu Ser Gln His Pro Ala Ala Pro Ser Ala Se - #r Asn Arg Ser Gly Ser# 30- Gly Phe Cys Glu Gln Val Phe Ile Lys Pro Gl - #u Val Phe Leu Ala Leu# 45- Gly Ile Val Ser Leu Met Glu Asn Ile Leu Va - #l Ile Leu Ala Val Val# 60- Arg Asn Gly Asn Leu His Ser Pro Met Tyr Ph - #e Phe Leu Leu Ser Leu# 80- Leu Gln Ala Asp Leu Leu Val Ser Leu Ser As - #n Ser Leu Glu Thr Ile# 95- Met Ile Val Val Ile Asn Ser Asp Ser Leu Th - #r Leu Glu Asp Gln Phe# 110- Ile Gln His Met Asp Asn Ile Phe Asp Ser Me - #t Ile Cys Ile Ser Leu# 125- Val Ala Ser Ile Cys Asn Leu Leu Ala Ile Al - #a Val Asp Arg Tyr Val# 140- Thr Ile Phe Tyr Ala Leu Arg Tyr His Ser Il - #e Met Thr Val Arg Lys145 1 - #50 1 - #55 1 -#60- Ala Leu Ser Leu Ile Val Ala Ile Trp Val Cy - #s Cys Gly Ile Cys Gly# 175- Val Met Phe Ile Val Tyr Ser Glu Ser Lys Me - #t Val Ile Val Cys Leu# 190- Ile Thr Met Phe Phe Ala Met Val Leu Leu Me - #t Gly Thr Leu Tyr Ile# 205- His Met Phe Leu Phe Ala Arg Leu His Val Gl - #n Arg Ile Ala Ala Leu# 220- Pro Pro Ala Asp Gly Leu Ala Pro Gln Gln Hi - #s Ser Cys Met Lys Gly225 2 - #30 2 - #35 2 -#40- Ala Val Thr Ile Thr Ile Leu Leu Gly Val Ph - #e Ile Phe Cys Trp Ala# 255- Pro Phe Phe Leu His Leu Val Leu Ile Ile Th - #r Cys Pro Thr Asn Pro# 270- Tyr Cys Ile Cys Tyr Thr Ala His Phe Asn Th - #r Tyr Leu Val Leu Ile# 285- Met Cys Asn Ser Val Ile Asp Pro Leu Ile Ty - #r Ala Phe Arg Ser Leu# 300- Glu Leu Arg Asn Thr Phe Lys Glu Ile Leu Cy - #s Gly Cys Asn Gly Met305 3 - #10 3 - #15 3 -#20- Asn Val Gly- (2) INFORMATION FOR SEQ ID NO:13:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..30#/function = "DegenerateRMATION: oligonucleot - #ide primer (sense)"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:# 30 TAYT DYTTCATCTG- (2) INFORMATION FOR SEQ ID NO:14:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..30#/function = "DegenerateRMATION: oligonucleot - #ide primer (sense)"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:# 30 TAKA TGARGGGGTC- (2) INFORMATION FOR SEQ ID NO:15:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1671 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA to mRNA- (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..393- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 394..1389- (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1390..1671- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:- AGCTTCCGAG AGGCAGCCGA TGTGAGCATG TGCGCACAGA TTCGTCTCCC AA - #TGGCATGG 60- CAGCTTCAAG GAAAATTATT TTGAACAGAC TTGAATGCAT AAGATTAAAG TT - #AAAGCAGA 120- AGTGAGAACA AGAAAGCAAA GAGCAGACTC TTTCAACTGA GAATGAATAT TT - #TGAAGCCC 180- AAGATTTTAA CGTGATGATG ATTAGAGTCG TACCTAAAAG AGACTAAAAA CT - #CCATGTCA 240- AGCTCTGGAC TTGTGACATT TACTCACAGC AGGCATGGCA ATTTTAGCCT CA - #CAACTTTC 300- AGACAGATAA AGACTTGGAG GAAATAACTG AGACGACTCC CTGACCCAGG AG - #GTTAAATC 360- AATTCAGGGG GACACTGGAA TTCTCCTGCC AGC ATG GTG AAC TC - #C ACC CAC CGT 414# Met Val Asn Ser Thr His Arg#5 1- GGG ATG CAC ACT TCT CTG CAC CTC TGG AAC CG - #C AGC AGT TAC AGA CTG 462Gly Met His Thr Ser Leu His Leu Trp Asn Ar - #g Ser Ser Tyr Arg Leu# 20- CAC AGC AAT GCC AGT GAG TCC CTT GGA AAA GG - #C TAC TCT GAT GGA GGG 510His Ser Asn Ala Ser Glu Ser Leu Gly Lys Gl - #y Tyr Ser Asp Gly Gly# 35- TGC TAC GCG CAA CTT TTT GTC TCT CCT GAG GT - #G TTT GTG ACT CTG GGT 558Cys Tyr Ala Gln Leu Phe Val Ser Pro Glu Va - #l Phe Val Thr Leu Gly# 55- GTG ATC AGC TTG TTG GAG AAT ATC TTA GAG AT - #T GTG GCA ATA GCC AAG 606Val Ile Ser Leu Leu Glu Asn Ile Leu Glu Il - #e Val Ala Ile Ala Lys# 70- AAC AAG AAT CTG CAT TCA CCC ATG TAC TTT TT - #C ATC TGC AGC TTG GCT 654Asn Lys Asn Leu His Ser Pro Met Tyr Phe Ph - #e Ile Cys Ser Leu Ala# 85- GTG GCT GAT ATG CTG GTG AGC GTT TCA AAT GG - #A TCA GAA ACC ATT ATC 702Val Ala Asp Met Leu Val Ser Val Ser Asn Gl - #y Ser Glu Thr Ile Ile# 100- ATC ACC CTA TTA AAC CGT ACA GAT ACG GAT GC - #A CAG AGT TTC ACA GTG 750Ile Thr Leu Leu Asn Arg Thr Asp Thr Asp Al - #a Gln Ser Phe Thr Val# 115- AAT ATT GAT AAT GTC ATT GAC TCG GTG ATC TG - #T AGC TCC TTG CTT GCA 798Asn Ile Asp Asn Val Ile Asp Ser Val Ile Cy - #s Ser Ser Leu Leu Ala120 1 - #25 1 - #30 1 -#35- TCC ATT TGC AGC CTG CTT TCA ATT GCA GTG GA - #C AGG TAC TTT ACT ATC 846Ser Ile Cys Ser Leu Leu Ser Ile Ala Val As - #p Arg Tyr Phe Thr Ile# 150- TTC TAT GCT CTC CAG TAC CAT AAC ATT ATG AC - #A GTT AAG CGG GTT GGG 894Phe Tyr Ala Leu Gln Tyr His Asn Ile Met Th - #r Val Lys Arg Val Gly# 165- ATC AGC ATA AGT TGT ATC TGG GCA GCT TGC AC - #G GTT TCA GGT ATT TTG 942Ile Ser Ile Ser Cys Ile Trp Ala Ala Cys Th - #r Val Ser Gly Ile Leu# 180- TTC ATC ATT TAC TCA GAT AGT AGT GCT GTC AT - #C ATC TGC CTC ATC ACC 990Phe Ile Ile Tyr Ser Asp Ser Ser Ala Val Il - #e Ile Cys Leu Ile Thr# 195- ATG TTC TTC ACC ATG CTG GCT CTC ATG GCT TC - #T CTC TAT GTC CAC CTG1038Met Phe Phe Thr Met Leu Ala Leu Met Ala Se - #r Leu Tyr Val His Leu200 2 - #05 2 - #10 2 -#15- TTC CTG ATG GCC AGG CTT CAC ATT AAG AGG AT - #T GCT GTC CTC CCC GGC1086Phe Leu Met Ala Arg Leu His Ile Lys Arg Il - #e Ala Val Leu Pro Gly# 230- ACT GGT GCC ATC CGC CAA GGT GCC AAT ATG AA - #G GGA GCG ATT ACC TTG1134Thr Gly Ala Ile Arg Gln Gly Ala Asn Met Ly - #s Gly Ala Ile Thr Leu# 245- ACC ATC CTG ATT GGC GTC TTT GTT GTC TGC TG - #G GCC CCA TTC TTC CTC1182Thr Ile Leu Ile Gly Val Phe Val Val Cys Tr - #p Ala Pro Phe Phe Leu# 260- CAC TTA ATA TTC TAC ATC TCT TGT CCT CAG AA - #T CCA TAT TGT GTG TGC1230His Leu Ile Phe Tyr Ile Ser Cys Pro Gln As - #n Pro Tyr Cys Val Cys# 275- TTC ATG TCT CAC TTT AAC TTG TAT CTC ATA CT - #G ATC ATG TGT AAT TCA1278Phe Met Ser His Phe Asn Leu Tyr Leu Ile Le - #u Ile Met Cys Asn Ser280 2 - #85 2 - #90 2 -#95- ATC ATC GAT CCT CTG ATT TAT GCA CTC CGG AG - #T CAA GAA CTG AGG AAA1326Ile Ile Asp Pro Leu Ile Tyr Ala Leu Arg Se - #r Gln Glu Leu Arg Lys# 310- ACC TTC AAA GAG ATC ATC TCT TCC TAT CCC CT - #G GGA GGC CTT TGT GAC1374Thr Phe Lys Glu Ile Ile Ser Ser Tyr Pro Le - #u Gly Gly Leu Cys Asp# 325- TTG TCT AGC AGA TAT TAAATGGGGA CAGAGCACGC AATATAGGA - #A CATCCATAAG1429Leu Ser Ser Arg Tyr 330- AGACTTTTTC ACTCTTACCC TACCTGAATA TTCTACTTCT GCAACAGCTT TC - #TCTTCCGT1489- GTAGGGTACT GGTTGAGATA TCCATTGTGT AAATTTAAGC CTATGATTTT TA - #ATGAGAAA1549- AAATGCCCAG TCTCTGTATT ATTTCCAATC TCATGCTACT TTTTTGGCCA TA - #AAATATGA1609- ATCTATGTTA TAGGTTGTAG GCACTGTGGA TTTACAAAAA GAAAAGTCCT TA - #TTAAAAGA1669# 1671- (2) INFORMATION FOR SEQ ID NO:16:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 332 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:- Met Val Asn Ser Thr His Arg Gly Met His Th - #r Ser Leu His Leu Trp# 15- Asn Arg Ser Ser Tyr Arg Leu His Ser Asn Al - #a Ser Glu Ser Leu Gly# 30- Lys Gly Tyr Ser Asp Gly Gly Cys Tyr Ala Gl - #n Leu Phe Val Ser Pro# 45- Glu Val Phe Val Thr Leu Gly Val Ile Ser Le - #u Leu Glu Asn Ile Leu# 60- Glu Ile Val Ala Ile Ala Lys Asn Lys Asn Le - #u His Ser Pro Met Tyr# 80- Phe Phe Ile Cys Ser Leu Ala Val Ala Asp Me - #t Leu Val Ser Val Ser# 95- Asn Gly Ser Glu Thr Ile Ile Ile Thr Leu Le - #u Asn Arg Thr Asp Thr# 110- Asp Ala Gln Ser Phe Thr Val Asn Ile Asp As - #n Val Ile Asp Ser Val# 125- Ile Cys Ser Ser Leu Leu Ala Ser Ile Cys Se - #r Leu Leu Ser Ile Ala# 140- Val Asp Arg Tyr Phe Thr Ile Phe Tyr Ala Le - #u Gln Tyr His Asn Ile145 1 - #50 1 - #55 1 -#60- Met Thr Val Lys Arg Val Gly Ile Ser Ile Se - #r Cys Ile Trp Ala Ala# 175- Cys Thr Val Ser Gly Ile Leu Phe Ile Ile Ty - #r Ser Asp Ser Ser Ala# 190- Val Ile Ile Cys Leu Ile Thr Met Phe Phe Th - #r Met Leu Ala Leu Met# 205- Ala Ser Leu Tyr Val His Leu Phe Leu Met Al - #a Arg Leu His Ile Lys# 220- Arg Ile Ala Val Leu Pro Gly Thr Gly Ala Il - #e Arg Gln Gly Ala Asn225 2 - #30 2 - #35 2 -#40- Met Lys Gly Ala Ile Thr Leu Thr Ile Leu Il - #e Gly Val Phe Val Val# 255- Cys Trp Ala Pro Phe Phe Leu His Leu Ile Ph - #e Tyr Ile Ser Cys Pro# 270- Gln Asn Pro Tyr Cys Val Cys Phe Met Ser Hi - #s Phe Asn Leu Tyr Leu# 285- Ile Leu Ile Met Cys Asn Ser Ile Ile Asp Pr - #o Leu Ile Tyr Ala Leu# 300- Arg Ser Gln Glu Leu Arg Lys Thr Phe Lys Gl - #u Ile Ile Ser Ser Tyr305 3 - #10 3 - #15 3 -#20- Pro Leu Gly Gly Leu Cys Asp Leu Ser Ser Ar - #g Tyr# 330- (2) INFORMATION FOR SEQ ID NO:17:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 978 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..975- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:- ATG AAC TCC TCC TCC ACC CTG ACT GTA TTG AA - #T CTT ACC CTG AAC GCC 48Met Asn Ser Ser Ser Thr Leu Thr Val Leu As - #n Leu Thr Leu Asn Ala# 15- TCA GAG GAT GGC ATT TTA GGA TCA AAT GTC AA - #G AAC AAG TCT TTG GCC 96Ser Glu Asp Gly Ile Leu Gly Ser Asn Val Ly - #s Asn Lys Ser Leu Ala# 30- TGT GAA GAA ATG GGC ATT GCC GTG GAG GTG TT - #C CTG ACC CTG GGT CTC 144Cys Glu Glu Met Gly Ile Ala Val Glu Val Ph - #e Leu Thr Leu Gly Leu# 45- GTC AGC CTC TTA GAG AAC ATC CTG GTC ATT GG - #G GCC ATA GTA AAG AAC 192Val Ser Leu Leu Glu Asn Ile Leu Val Ile Gl - #y Ala Ile Val Lys Asn# 60- AAA AAC CTG CAC TCA CCC ATG TAC TTC TTT GT - #G GGC AGC TTA GCC GTG 240Lys Asn Leu His Ser Pro Met Tyr Phe Phe Va - #l Gly Ser Leu Ala Val# 80- GCC GAC ATG CTG GTG AGC ATG TCC AAT GCC TG - #G GAG ACT GTC ACC ATA 288Ala Asp Met Leu Val Ser Met Ser Asn Ala Tr - #p Glu Thr Val Thr Ile# 95- TAC TTG CTA AAT AAT AAA CAC CTG GTG ATA GC - #C GAC ACC TTT GTG CGA 336Tyr Leu Leu Asn Asn Lys His Leu Val Ile Al - #a Asp Thr Phe Val Arg# 110- CAC ATC GAC AAC GTG TTC GAC TCC ATG ATC TG - #C ATC TCT GTG GTG GCC 384His Ile Asp Asn Val Phe Asp Ser Met Ile Cy - #s Ile Ser Val Val Ala# 125- TCG ATG TGC AGT TTG CTG GCC ATT GCG GTG GA - #T AGG TAC ATC ACC ATC 432Ser Met Cys Ser Leu Leu Ala Ile Ala Val As - #p Arg Tyr Ile Thr Ile# 140- TTC TAT GCC TTG CGC TAC CAC CAC ATC ATG AC - #C GCG AGG CGC TCG GGG 480Phe Tyr Ala Leu Arg Tyr His His Ile Met Th - #r Ala Arg Arg Ser Gly145 1 - #50 1 - #55 1 -#60- GTG ATC ATC GCC TGC ATT TGG ACC TTC TGC AT - #A AGC TGC GGC ATT GTT 528Val Ile Ile Ala Cys Ile Trp Thr Phe Cys Il - #e Ser Cys Gly Ile Val# 175- TTC ATC ATC TAC TAT GAG TCC AAG TAT GTG AT - #C ATT TGC CTC ATC TCC 576Phe Ile Ile Tyr Tyr Glu Ser Lys Tyr Val Il - #e Ile Cys Leu Ile Ser# 190- ATG TTC TTC ACC ATG CTG TTC TTC ATG GTG TC - #T CTG TAT ATA CAC ATG 624Met Phe Phe Thr Met Leu Phe Phe Met Val Se - #r Leu Tyr Ile His Met# 205- TTC CTC CTG GCC CGG AAC CAT GTC AAG CGG AT - #A GCA GCT TCC CCC AGA 672Phe Leu Leu Ala Arg Asn His Val Lys Arg Il - #e Ala Ala Ser Pro Arg# 220- TAC AAC TCC GTG AGG CAA AGG ACC AGC ATG AA - #G GGG GCT ATT ACC CTC 720Tyr Asn Ser Val Arg Gln Arg Thr Ser Met Ly - #s Gly Ala Ile Thr Leu225 2 - #30 2 - #35 2 -#40- ACC ATG CTA CTG GGG ATT TTC ATT GTC TGC TG - #G TCT CCC TTC TTT CTT 768Thr Met Leu Leu Gly Ile Phe Ile Val Cys Tr - #p Ser Pro Phe Phe Leu# 255- CAC CTT ATC TTA ATG ATC TCC TGC CCT CAG AA - #C GTC TAC TGC TCT TGC 816His Leu Ile Leu Met Ile Ser Cys Pro Gln As - #n Val Tyr Cys Ser Cys# 270- TTT ATG TCT TAC TTC AAC ATG TAC CTT ATA CT - #C ATC ATG TGC AAC TCC 864Phe Met Ser Tyr Phe Asn Met Tyr Leu Ile Le - #u Ile Met Cys Asn Ser# 285- GTG ATC GAT CCT CTC ATC TAC GCC CTC CGC AG - #C CAA GAG ATG CGG AGG 912Val Ile Asp Pro Leu Ile Tyr Ala Leu Arg Se - #r Gln Glu Met Arg Arg# 300- ACC TTT AAG GAG ATC GTC TGT TGT CAC GGA TT - #C CGG CGA CCT TGT AGG 960Thr Phe Lys Glu Ile Val Cys Cys His Gly Ph - #e Arg Arg Pro Cys Arg305 3 - #10 3 - #15 3 -#20# 978 AT TAALeu Leu Gly Gly Tyr 325- (2) INFORMATION FOR SEQ ID NO:18:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 325 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:- Met Asn Ser Ser Ser Thr Leu Thr Val Leu As - #n Leu Thr Leu Asn Ala# 15- Ser Glu Asp Gly Ile Leu Gly Ser Asn Val Ly - #s Asn Lys Ser Leu Ala# 30- Cys Glu Glu Met Gly Ile Ala Val Glu Val Ph - #e Leu Thr Leu Gly Leu# 45- Val Ser Leu Leu Glu Asn Ile Leu Val Ile Gl - #y Ala Ile Val Lys Asn# 60- Lys Asn Leu His Ser Pro Met Tyr Phe Phe Va - #l Gly Ser Leu Ala Val# 80- Ala Asp Met Leu Val Ser Met Ser Asn Ala Tr - #p Glu Thr Val Thr Ile# 95- Tyr Leu Leu Asn Asn Lys His Leu Val Ile Al - #a Asp Thr Phe Val Arg# 110- His Ile Asp Asn Val Phe Asp Ser Met Ile Cy - #s Ile Ser Val Val Ala# 125- Ser Met Cys Ser Leu Leu Ala Ile Ala Val As - #p Arg Tyr Ile Thr Ile# 140- Phe Tyr Ala Leu Arg Tyr His His Ile Met Th - #r Ala Arg Arg Ser Gly145 1 - #50 1 - #55 1 -#60- Val Ile Ile Ala Cys Ile Trp Thr Phe Cys Il - #e Ser Cys Gly Ile Val# 175- Phe Ile Ile Tyr Tyr Glu Ser Lys Tyr Val Il - #e Ile Cys Leu Ile Ser# 190- Met Phe Phe Thr Met Leu Phe Phe Met Val Se - #r Leu Tyr Ile His Met# 205- Phe Leu Leu Ala Arg Asn His Val Lys Arg Il - #e Ala Ala Ser Pro Arg# 220- Tyr Asn Ser Val Arg Gln Arg Thr Ser Met Ly - #s Gly Ala Ile Thr Leu225 2 - #30 2 - #35 2 -#40- Thr Met Leu Leu Gly Ile Phe Ile Val Cys Tr - #p Ser Pro Phe Phe Leu# 255- His Leu Ile Leu Met Ile Ser Cys Pro Gln As - #n Val Tyr Cys Ser Cys# 270- Phe Met Ser Tyr Phe Asn Met Tyr Leu Ile Le - #u Ile Met Cys Asn Ser# 285- Val Ile Asp Pro Leu Ile Tyr Ala Leu Arg Se - #r Gln Glu Met Arg Arg# 300- Thr Phe Lys Glu Ile Val Cys Cys His Gly Ph - #e Arg Arg Pro Cys Arg305 3 - #10 3 - #15 3 -#20- Leu Leu Gly Gly Tyr 325- (2) INFORMATION FOR SEQ ID NO:19:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..32#/function = "DegenerateRMATION: oligonucleot - #ide primer (antisense)"- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:# 30 TATG ACGGCCATGG__________________________________________________________________________

Claims

1. A method for characterizing a compound as a mammalian MC-3 or MC-4 melanocortin receptor agonist that inhibits feeding behavior in an animal, the method comprising the steps of:

(a) providing a panel comprising a first mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the .alpha.-MSH receptor identified by Seq. ID Nos. 4 or 6, a second mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the ACTH receptor identified by Seq. ID Nos. 8 or 10, a third mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-3 receptor identified by Seq. ID No. 12, a fourth mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-4 receptor identified by Seq. ID No. 16, and a fifth mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-5 receptor identified by Seq ID No. 18, wherein each mammalian cell expresses the melanocotin receptor encoded by the recombinant expression construct comprising tie cell;

(b) contacting each of the cells of the panel with a test compound to be characterized as an agonist of a mammalian melanocortin receptor;

(c) detecting binding of the test compound to each of the mammalian melanocortin receptors by assaying for a metabolite produced in the cells that bind the compound, wherein detection of the metabolite indicates that the test compound is an agonist of the melanocortin receptor;

(d) selecting the test compounds that are MC-3 or MC-4 melanocortin receptor agonists, and

(e) determining whether the MC-3 or MC-4 melanocortin receptor agonist inhibits feeding behavior in an animal.

2. The method of claim 1, wherein the metabolite detected in subpart (c) is cyclic AMP.

3. The method of claim 1, each of the cells further comprising a recombinant expression construct encoding a cyclic AMP responsive element (CRE) transcription factor binding site operatively linked to a nucleic acid sequence encoding a protein capable of producing a detectable metabolite.

4. The method of claim 3, wherein the nucleic acid sequence encodes .beta.-galactosidase.

5. The method of claim 3, wherein the recombinant expression construct is pCRE/.beta.-galactosidase.

6. The method of claim 3, wherein the cells encoding each of the melanocortin receptors are cultured separately from each other and wherein the detectable metabolite produced by the protein encoded by the recombinant expression construct is produced by binding of the test compound to the mammalian melanocortin receptor encoded by each of the cells of the panel.

7. The method of claim 1 wherein the test compound is an agonist of the MC-3 mammalian melanocortin receptor.

8. The method of claim 1 wherein the test compound is an agonist of the MC-4 mammalian melanocortin receptor.

9. The method of claim 3 wherein the test compound is an agonist of the MC-3 mammalian melanocortin receptor.

10. The method of claim 3 wherein the test compound is an agonist of the MC-4 mammalian melanocortin receptor.

11. A method for characterizing a compound as a mammalian MC-3 or MC-4 melanocortin receptor antagonist that stimulates feeding behavior in an animal, the method comprising the steps of:

(a) providing a panel comprising a first mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the .alpha.-MSH receptor identified by Seq. ID Nos. 4 or 6, a second mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the ACTH receptor identified by Seq. ID Nos. 8 or 10, a third mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-3 receptor identified by Seq. ID No. 12, a fourth mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-4 receptor identified by Seq. ID No. 16, and a fifth mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-5 receptor identified by Seq. ID No. 18, wherein each mammalian cell expresses the melanocortin receptor encoded by the recombinant expression construct comprising the cell,

(b) contacting each of the cells of the panel with an agonist of the mammalian melanocortin receptor in an amount sufficient to produce a detectable amount of a metabolite produced in the cells that bind the agonist, in the presence or absence of a test compound to be characterized as an antagonist of a mammalian melanocortin receptor;

(c) detecting the amount of the metabolite produced in each cell in the panel in the presence of the test compound with the amount of the metabolite produced in each cell in the panel in the absence, wherein the test compound is determined to be an antagonist of melanocortin binding if the amount of the metabolite produced in the presence of the test compound is less than the amount of the metabolite produced in the absence of the test compound;

(d) selecting the test compounds that are MC-3 or MC-4 melanocortin receptor antagonist agonists, and

(e) determining whether the MC-3 or MC-4 melanocortin receptor antagonist stimulates feeding behavior in an animal.

12. The method of claim 11, wherein the metabolite detected in subpart (c) is cyclic AMP.

13. The method of claim 11, each of the cells further comprising a recombinant expression construct encoding a cyclic AMP responsive element (CRE) transcription factor binding site operatively linked to a nucleic acid sequence encoding a protein capable of producing a detectable metabolite.

14. The method of claim 13, wherein the nucleic acid sequence encodes .beta.-galactosidase.

15. The method of claim 13, wherein the recombinant expression construct is pCRE/.beta.-galactosidase.

16. The method of claim 13, wherein the cells encoding each of the melanocortin receptors are cultured separately from each other and wherein the detectable metabolite produced by the protein encoded by the recombinant expression construct is produced by binding of the test compound to the mammalian melanocortin receptor encoded by each of the cells of the panel.

17. The method of claim 11 wherein the test compound is an antagonist of the MC-3 mammalian melanocortin receptor.

18. The method of claim 11 wherein the test compound is an antagonist of the MC-4 mammalian melanocortin receptor.

19. The method of claim 13 wherein the test compound is an antagonist of the MC-3 mammalian melanocortin receptor.

20. The method of claim 13 wherein the test compound is an antagonist of the MC-4 mammalian melanocortin receptor.

21. A biological screening panel for determining the mammalian melanocortin receptor agonist/antagonist profile of a test compound for the MC3 or MC-4 receptors, wherein the panel is used to identify compounds that modulate feeding behavior in an animal, the panel comprising a first mammalian cell consisting of a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-3 receptor identified by Seq. ID No. 12, and a second mammalian cell comprising a recombinant expression construct encoding a mammalian melanocortin receptor that is the MC-4 receptor identified by Seq. ID No. 16, wherein each mammalian cell expresses the melanocortin receptor encoded by the recombinant expression construct comprising the cell, and wherein compounds that modulate feeding behavior in a animal are selected from the MC-3/MC-4 mammalian melanocortin receptor agonists and antagonists.